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Summary 
 
Bacillus anthracis is the causative agent of the infectious disease anthrax. The disease is 
caused after taking up the spores by either inhalation, ingestion or through skin lesion. 
They then germinate inside the body and start secreting the tripartite anthrax toxin. This 
toxin can hijack the two anthrax toxin receptors, CMG2 (ANTXR2) or TEM8 
(ANTXR1) to enter host cells. Once inside the host cell, the toxin will start to interfere 
with essential cellular pathways, ultimately leading to severe damage and death. 
The two anthrax toxin receptors have been well described in the context of anthrax toxin 
pathogenesis. Their normal, physiological function however has been studied far less. 
Mutations in either one of the two proteins leads to a severe genetic disease, underlining 
the importance CMG2 and TEM8 normally have.  
My thesis therefore aimed at better understanding the physiological function of the two 
receptors.  
In a first part, we chose to study the impact of N-glycosylation on the folding, trafficking 
and, finally, the function of CMG2 and TEM8. N-glycosylation is a very common 
posttranslational modification and has been shown to play an important role in various 
cellular processes such as protein folding, stability, cell adhesion, endocytosis, cell-cell 
recognition and trafficking. We show that both receptors are glycosylated on the 
predicted sites, with varying impacts on different functions of the proteins. TEM8 
crucially relies on the presence of the sugar sidechains, as a non-glycosylated mutant will 
fail to fold, will be retained in the ER and is non-functional. CMG2 is less sensitive to 
defects in glycosylation, even a non-glycosylated mutant will be able to reach its target 
destination and function correctly. However, in the simultaneous presence of mutations 
seen in Hyaline Fibromatis Syndrome, N-glycosylation seems to function as a genetic 
buffer, stabilizing the mutated protein. N-glycosylation helps to increase the folding 
capacity of both receptors and therefore impacts on their physiological function. 
In a second part our objective was to find new interaction partners of CMG2 and study 
their effect on toxin endocytosis as a suitable functional output. We identified 4 new 
proteins that regulate anthrax toxin entry via CMG2: RNF41 and Cbl, both ubiquitin E3 
ligases, MARK2, a serine-threonine kinase and USP8, a deubiquitinating enzyme. In the 
absence of any of these four proteins, toxin entry into cells was strongly delayed or 
blocked. Of these four new regulators, Cbl and MARK2 are conserved for toxin entry 
via TEM8. We found that both RNF41 and Cbl can ubiquitinate CMG2, but regulate 
different steps of toxin entry. We also established a flow cytometry-based endocytosis 
assay for CMG2 and TEM8, enabling us to look at endocytosis and internalization 
kinetics in the absence of the pathogenic ligand anthrax toxin. Both receptors 
continuously internalize from the plasma membrane an endocytic process, which is 
regulated by ligand-binding and the multimerization of the receptors. Interestingly, 
CMG2 and TEM8 show a striking difference in their endocytosis rate, suggesting an 
important functional role of this behavior as well.  
 
Keywords: CMG2, N-glycosylation, anthrax toxin, endocytosis 
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Zusammenfassung 
 
Die Infektionskrankheit Anthrax (Milzbrand) wird durch den bakteriellen Erreger Bacillus 
anthracis verursacht. Die Krankheit wird ausgelöst nach der Aufnahme der Sporen in den 
Körper des Wirts und der Keimung der Sporen. Dies führt zur Produktion und 
Sekretion des dreiteiligen Anthraxtoxins. Um in die Zelle zu gelangen, macht sich das 
Toxin die beiden zellulären Anthraxrezeptoren CMG2 (ANTXR2) und TEM8 
(ANTXR1) zu Nutze. Sobald das Toxin in die Zelle gelangt ist, dereguliert es essentielle 
zelluläre Signalwege, die letzendlich zu grossem Schaden und Zelltod führen. 
Obwohl beide Toxinrezeptoren im Kontext von Milzbrand gut erforscht sind, ist ihre 
physiologische Rolle bis jetzt unklar. Mutationen in jedem der beiden Rezeptoren führen 
zu einer schweren genetischen Erkrankung. Dies unterstreicht die wichtige Rolle, die 
CMG2 und TEM8 normalerweise im Körper spielen. 
Meine Doktorarbeit hatte zum Ziel, die physiologische Funktion dieser beiden 
Rezeptoren besser zu verstehen. 
In einem ersten Projekt haben wir die Auswirkungen von N-Glykosylierung auf Faltung, 
Transport und Funktion von CMG2 und TEM8 untersucht. N-Glykosylierung ist eine 
häufig vorkommende posttranslationale Modifikation, die eine wichtige Rolle in 
verschiedenen, essentiellen zellulären Prozessen spielt. Dazu gehören die Faltung und 
Stabilität von Proteinen, Zellädhesion, Endozytose, Zell-Zell-Erkennung und 
Proteintransport. Wir konnten zeigen, dass beide Rezeptoren glykosyliert sind und dass 
dies verschiedene Auswirkungen auf die diversen Funktionen der Proteine hat. Für 
TEM8 ist die Glykosylierung äusserst wichtig. Ein nicht-glykosyliertes Protein kann sich 
nicht korrekt falten, wird im ER zurückbehalten und ist nicht funktionsfähig. CMG2 
hingegen ist resistenter gegenüber einenm Verlust der Glykosylgruppen. Auch ein nicht-
glykosyliertes Protein kann sein zelluläres Ziel erreichen und korrekt funktionieren. 
Interessanterweise scheint, bei gleichzeitigem Vorkommen von Mutationen des Hyalinen 
Fibromatosis Syndrom, Glykosylierung eine genetische Pufferrolle einzunehmen. Dies 
stabilisiert das mutierte Protein. N-Glykosylierung von CMG2 und TEM8 hilft den 
Proteinen, sich zu falten und hat folglich einen Einfluss auf deren physiologische 
Funktion. 
Im zweiten Projekt war das Ziel, neue Interaktionspartner von CMG2 zu finden. Zudem 
wollten wir deren Effekt auf die Endozytose von Anthraxtoxin als geeigneten  
Funktionstest untersuchen. Wir haben vier neue Proteine gefunden, die die Endozytose 
von Anthraxtoxin via CMG2 regulieren: RNF41 und Cbl, beides E3-Ubiquitin-Ligasen, 
MARK2, eine Serin-Threonin-Kinase und USP8, ein deubiquitinierendes Enzym. Ohne 
jedes einzelne dieser vier Proteine war die Toxinendozytose stark verlangsamt oder 
blockiert. Von diesen vier Proteinen sind Cbl und MARK2 auch in der Endozytose von 
Anthraxtoxin via TEM8 involviert. RNF41 und Cbl regulieren beide die Ubiquitinierung 
von CMG2, sind aber an verschiedenen Etappen des Prozesses beteiligt. Wir haben des 
weiteren einen neuen, auf dem Prinzip der Durchflusszytometrie basierenden Test 
entwickelt, der es uns ermöglicht, die Endozytose von CMG2 und TEM8 und deren 
Kinetik in der Abwesenheit des pathogenen Ligandes Anthraxtoxin zu untersuchen. 
Beide Rezeptoren internalisieren kontinuierlich von der Zelloberfläche, ein Prozess, der 
von dem Binden eines Liganden und der Multimerisierung des Rezeptors abhängt. 
CMG2 und TEM8 internalisieren mit sehr unterschiedlichen Zeiten, was auf ein 
unterschiedliches physiologisches Verhalten hindeuten könnte.  
 
Schlüsselwörter: CMG2, N-Glykosylierung, Anthraxtoxin, Endozytose 
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Abbreviations 
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AAA ATPase ATPases Associated with diverse cellular 
Activities 
ANTXR Anthrax toxin receptor 
Cbl Casitas B-lineage lymphoma 
CBD Cytoskeleton binding domain 
CIE Clathrin independent endocytosis 
CMG2 Capillary morphogenesis gene 2 
CME Clathrin mediated endocytosis 
DUB Deubiquitinating enzyme 
ECM Extracellular matrix 
EE Early endosome 
EGFR Epidermal growth factor receptor 
EF Edema factor 
ER Endoplasmic reticulum 
ERAD ER associated degradation 
ERQC ER quality control 
ESCRT Endosomal sorting complex required for transport
FRAP Fluorescence recovery after photobleaching 
GAPO Growth retardation, alopecia, pseudoanodontia  
and optic atrophy 
GPCR G-protein coupled receptor 
HFS Hyaline Fibromatosis Syndrome 
ILV Intralumenal vesicles 
LE Late endosome 
LF Lethal factor 
MARK2 MAP/microtubule affinity regulating kinase 2 
MIDAS Metal ion dependent adhesion site 
MVB Multivesicular body 
OST Oligosaccharyl transferase 
PA Protective antigen 
PI Phosphatidylinositol 
PM Plasma membrane 
RNF41 RING finger protein 41 
RTK Receptor tyrosine kinase 
TEM8 Tumor endothelial marker 8 
TM Transmembrane 
USP8 Ubiquitin specific peptidase 8 
vWA Von Willebrand Factor A 
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I. Introduction 
 
Anthrax is an infectious disease caused by the Gram-positive bacterium Bacillus anthracis. 
While it is a well known old disease that often affects cattle or humans in contact with 
animals, it received public attention after the terrorist attacks of 9/11, when letters 
containing the infectious spores were sent to governmental institutions in the US, leading 
to 11 deaths. As many pathogens, B. anthracis has developed strategies to hijack the host 
cell machinery to colonize its host and spread. One of the major virulence factors is the 
anthrax toxin, the entry of which into cells of the host crucially relies on the presence of 
anthrax toxin receptors. In this thesis we have studied folding and endocytosis of the two 
anthrax toxin receptors, both in a physiological as well as in a pathological context.  
1. The two anthrax toxin receptors 
 
Both CMG2 and TEM8, also known as anthrax toxin receptors (ANTXR 2 and 1 
respectively) were initially found in screens of physiological/pathological functions. Yet 
they have been more famously studied in their role as toxin receptors during infection. 
Here, I will talk first about their function in a physiological context and will discuss the 
toxin entry in a later chapter. 
 
CMG2 protein 
 
Capillary morphogenesis gene 2 (CMG2) was initially discovered in an in vitro capillary 
formation assay in endothelial cells, where it was strongly upregulated after 8h [1].  
CMG2 is a ubiquitiously expressed protein, highly conserved but only present in 
vertebrates [2]. It is a 55kDa type I transmembrane (TM) protein, which contains an 
extracellular von Willebrand factor type A (vWA) domain, followed by an Ig-like domain, 
a TM span of 23 amino acids and a tail of 148 amino acids, which is predicted to be 
unfolded [2] (Fig.1A).  There are four different isoforms [3] (Fig.1B), with isoform 4 
being the one mainly studied in this work.  
 
 
Fig .1 :  Struc ture  o f  CMG2 A) Schematic structure of CMG2 based on crystal structure of the vWA 
domain (1TZN) and modeling of the Ig-like domain [4]. B)  Depiction of the 4 isoforms of CMG2. All are TM 
proteins, except isoform 3 that is predicted to be secreted. The last 13 amino acids of isoform 4 differ from isoform 
1 and 2. 
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The vWA domain is a protein-protein interaction domain, which is found in several 
proteins that interact with proteins of the extracellular matrix (ECM). The most 
prominent examples of these vWA-containing proteins are integrins, where the domain 
is called I (inserted) domain [5]. The vWA domain of CMG2 contains a metal ion-
dependent adhesion site (MIDAS), which is responsible for ligand binding [3].  
The function of the Ig-like domain of CMG2 is so far still unknown. But it features two 
disulfide bonds, which are necessary for correct folding of the protein [4] and for proper 
insertion of the anthrax toxin into the endosomal membrane during anthrax toxin entry 
[6] (see in a later chapter). It also harbors two N-glycosylation sites, which are 
advantageous for protein folding, especially in the presence of other destabilizing 
mutations [7]. 
Directly after the TM span, there are two cysteines that can be palmitoylated, with a third 
site further downstream (S. Blaskovic, unpublished work). Palmitoylation is the reversible 
addition of a C16 fatty acid to cysteine residues of proteins, both soluble and TM [8]. For 
CMG2 this posttranslational modification affects protein stability at the cell surface (S. 
Blaskovic, unpublished work). The tail of CMG2 is predicted to be unstructured [9]. 
Disordered domains occur quite frequently in proteins and could be important for 
signaling and regulation [10]. The exact function of this domain in CMG2 remains to be 
determined. 
 
TEM8 protein 
 
The only other protein homologous to CMG2 is Tumor endothelial marker 8 (TEM8).  
It is also a type I TM protein and the two proteins share around 60% homology in the 
vWA domain and 68% identity in the first 145 residues of the cytoplasmic tail [11]. The 
tail of CMG2 and TEM8 contains a highly conserved cytoskeleton-binding domain 
(CBD), which was initially identified in TEM8 [12]. The vWA domain of TEM8 contains 
two N-glycosylation sites and one in the Ig-like domain, which is conserved between 
CMG2 and TEM8. The glycan sidechains are important for TEM8 folding and 
trafficking, as a glycosylation-deficient mutant cannot fold correctly, will be retained in 
the ER and degraded [7]. 
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Fig .2 :  Sequence  a l i gnement  be tween CMG2 and TEM8 TEM8 (ANTXR1) and CMG2 
(ANTXR2) were aligned and the protein domains are indicated [7]. 
 
TEM8 is expressed in a variety of tissues, especially in epithelial cells [13], but was 
initially identified as upregulated during tumor angiogenesis [14]. 
 
Physiological role of CMG2 and TEM8 
 
Almost 15 years after their discovery, the physiological role of CMG2 and TEM8 
remains elusive. However, there are some promising leads for the two proteins, 
stemming from both in vitro and in vivo work. 
The discovery of both proteins is linked to angiogenesis. CMG2 is expressed in the 
vascular endothelium of mice and in both endothelial cells of normal and cancer tissues 
[15]. In the same study, it was also found to be important for proliferation and capillary 
formation in Human Umbilical Vein Endothelial Cells (HUVECs) [15]. Therefore, 
efforts are undertaken to develop CMG2 as a potential therapeutic target in tumor 
angiogenesis [16]. 
TEM8, in addition to being highly expressed in tumor angiogenesis, was found to be 
upregulated in vasculature during the embryonic development in mice, yet undetectable 
in adult tissues [17].  Also, physiological angiogenesis is not impaired in TEM8 knockout 
mice [18]. It seems that vessel density and patterning during a specific phase of 
embryonic development are controlled by TEM8 in response to the canonical Wnt 
signaling pathway [19]. Missense mutations in TEM8 were also shown to be one of the 
causes of infantile hemangioma, which are regions of increased and disorganized 
angiogenesis [20]. This role in angiogenesis has also linked TEM8 increasingly to cancer 
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and its expression has been observed in a variety of cancers. Breast cancer cell lines that 
express TEM8 are more aggressive and invasive, also in an in vivo mouse model [21]. 
Also, TEM8 has been described as a marker for cancer stem cells [22] and cancer-specific 
circulating endothelial cells [23]. Therefore, TEM8 has increasingly become the focus of 
anti-cancer therapy, targeting cancer angiogenesis and thereby cutting off the supply line 
of the tumor [24, 25]. 
Another common theme of CMG2 and TEM8 is the link to the Wnt signaling pathway. 
Both receptors can interact with the Wnt coreceptor LRP5 and 6 [26, 27]. Also, TEM8 
seems to function as a modulator/enhancer of the Wnt signaling pathway in 
developmental angiogenesis [19] and in cancer stem cells [22]. 
The link to Wnt seems evolutionary conserved. The closest homolog of CMG2 in 
zebrafish, Antxr2a, is responsible for polarization, again through interaction with the 
Wnt signaling pathway [28]. It is responsible for correct positioning of the mitotic 
spindle during zebrafish development. The Wnt pathway leads to a formation of a 
cortical actin cap in dividing epiblast cells. This will recruit Antxr2a and it will act as a 
RhoA effector, activating zDia2 that exerts a force on the spindle, ensuring correct 
orientation and subsequent cell division [28]. 
Both receptors can also bind actin in human cells by a domain of approximately 30 
residues in the cytoplasmic tail [12 and J.Bürgi, unpublished work]. TEM8 was found to 
bind to actin, but this interaction was abolished when it bound to its surrogate ligand 
anthrax toxin on the extracellular part [29-31]. The same is true for CMG2 (J. Bürgi, 
unpublished work), but in contrast to TEM8, CMG2 in tissue culture cells it seems to be 
constantly occupied at steady state. Therefore, its ability to bind actin was only 
discovered recently with the help of a ligand-binding deficient mutant, D50A (J. Bürgi, 
unpublished work). Many of these studies rely on the binding of anthrax toxin as a 
surrogate ligand, as the true nature of the physiological binding partner of both receptors 
remains controversial. 
In the first description of CMG2 in 2001, it was reported that the recombinant vWA of 
CMG2 can in vitro bind to the ECM proteins collagen IV and laminin [1]. This suggests a 
role in binding to or regulating the ECM. Strengthening this hypothesis, CMG2 
knockout mice show an accumulation of collagen I, VI and fibronectin in the uterus [32, 
33]. TEM8 as well was found to bind to ECM proteins, but in this case it was collagen I 
and VI [34, 35]. TEM8 knockout mice show also an accumulation of ECM in the uterus, 
but also additionally in the ovaries and the skin and enlarged teeth [36]. How this relates 
to angiogenesis is unclear, but the dysregulation of ECM is the link to the human 
diseases that are caused by mutations in CMG2 and TEM8: Hyaline Fibromatosis and 
GAPO syndrome. 
 
Diseases associated with CMG2 and TEM8 
 
Hyaline Fibromatosis Syndrome (HFS) is a rare autosomal, recessive disease caused by 
mutations in cmg2 [37, 38]. The main disease symptom of HFS is the accumulation of 
ECM in organs and skin [39, 40]. These nodules seem to primarily form at sites of 
mechanical stress [41] and seem to mainly consist of collagen VI and glycosaminoglycans 
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[42, 43]. Other symptoms include failure to thrive, joint flexion contracture, recurrent 
infections and diarrhea and a higher susceptibility to bone lesions [2, 44]. Patients do not 
display mental retardation, consistent with the absence of CMG2 expression in brain 
[41]. For more severe cases, patients rarely survive their first two years. Mild cases are 
highly disfiguring and debilitating but patients can survive well into their adult years.  
The mutations of CMG2 causing HFS characterized so far are all loss-of-function 
mutations and can generally be classified into 4 classes [2]. Class I consists of mutations 
in the vWA domain that do not affect folding or targeting to the plasma membrane but 
cannot bind the ligand, such as D50N. Class II are mutations in either vWA or Ig-like 
domain that affect folding of the protein, thereby leading to ER retention and 
degradation [45, 46]. Class III groups mutations that lead to mRNA degradation by the 
nonsense-mediated degradation (NMD) pathway due to the insertion of a premature 
stop codon [9]. Class IV mutations map to the cytosolic tail and are targeted properly to 
the PM. However, their function is impaired, through mechanisms that remain to be 
identified. 
GAPO stands for growth retardation, alopecia, pseudoanodontia and optic atrophy and 
is caused by mutations in TEM8 [47].  Again, symptoms include accumulation of ECM 
but also dental abnormalities, which fits well with symptoms found in TEM8 knockout 
mice [18, 47, 48]. Patients display characteristic facial features, such as frontal bossing, 
broad forehead, widely spaced eyes, sparse facial hair including eyebrows and eyelashes 
and thickened lips, making the condition easily recognizable [47, 48]. 
So far only around 30 patients have been diagnosed with GAPO syndrome. The 
causative gene having been identified only very recently, no genotype-phenotype analyses 
have been reported yet. 
 
2. Endocytosis and its regulation 
 
Endocytosis in general 
  
Endocytosis is a term that describes the general uptake for a plethora of substrates into 
the cell from the plasma membrane by vesicular traffic. Endocytic cargo can be liquid or 
solid, can be receptor-mediated or unspecific, includes components of the PM such as 
lipids or membrane proteins but also extracellular particles as diverse as ECM proteins, 
nutrients or pathogens, both viral and bacterial. 
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Fig .3 :  Schemat i c  dep i c t ion  o f  pathways  in to  the  c e l l  There are several pathways into the cell. In 
general, they can be separated into clathrin-dependent, caveolin-dependent and other, clathrin- and caveolin-
independent mechanisms. All pathways eventually converge at the level of early endosomes, the major hub for 
incoming cargo. Image from [49] 
To get into a cell, endocytic cargo can take many routes. There is phagocytosis and 
macropinocytosis, both pathways that involve a large deformation of the membrane 
towards the outside. These entryways will not be discussed further here. 
Other pathways include clathrin-dependent, caveolin-dependent and clathrin- and 
caveolin-independent mechanisms (Fig.3).  
Clathrin-mediated endocytosis 
Although by far not the only pathway for endocytic cargo to enter a cell, clathrin-
mediated endocytosis (CME) is the most extensively described and studied endocytic 
pathway and appears in all eukaryotic cells. Knockout of clathrin or several other core
proteins of CME are lethal in flies, worms and mice [50-53], underlining the importance 
of this process.   
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Fig .4 :  Five  s t eps  in  c la thr in -media t ed  endocy tos i s  A) Depicted are the five steps of clathrin-mediated 
endocytosis (CME): nucleation, cargo selection, coat assembly, scission and uncoating with the key proteins of every 
step. B) Interactome of the proteins involved in CME, with the major hub proteins being AP2 and clathrin. 
Image from [49] 
Endocytosis via clathrin can be separated into 5 different steps: initiation, cargo 
selection, coat assembly, scission and finally uncoating.  
For the initiation, an invagination of the PM at the site of endocytosis will form. It seems 
that the definition of the site, where this invagination will occur, might be mediated by 
binding of FCHo1/2, EPS15 and intersectins [54, 55]. They preferentially bind to 
PI(4,5)P2 at the PM and FCHo proteins have membrane-bending activity, thereby 
helping the formation of a stable invagination [54, 56]. 
After this, the endocytic cargo needs to be selected. This process is mediated by AP2, 
one of the core proteins of CME and other adaptor proteins, binding to AP2. AP2 can 
either bind receptors directly or it binds adaptor proteins, which in turn bind receptors at 
the PM [57-59]. The specificity of AP-2 acting preferentially at the PM stems from its 
ability to bind PI(4,5)P2 [60, 61]. AP-2 not only helps in cargo selection but will also 
recruit clathrin from the cytosol to the nascent pits [62]. The clathrin triskelia will form a 
lattice around the curvature, thereby stabilizing the curvature. However, it has been 
observed that clathrin can also assemble on flat membranes for certain cell types and will 
form a stable lattice with a comparable low turnover rate [63], challenging the notion of 
clathrin only being assembled after membrane curvature has been established. Indeed, a 
recent finding shows that clathrin seems to be first present as a flat lattice and during the 
formation of a clathrin-coated pit undergoes continuous rearrangement as curvature 
increases [64].  
Once the clathrin-coated vesicle has formed, it needs to pinch off from the PM to traffic 
towards the endocytic pathway. For this, the action of dynamin is needed [65, 66]. 
Dynamin is a GTPase and will form a ring-like helix structure around the “neck” of the 
budding vesicle [67]. The specific recruitement of dynamin to the strongly curved neck 
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of a clathrin coated pit (CCP) can either be mediated by curvature-sensing proteins with 
a BAR domain such as amphiphysin or endophilin [68, 69] or by curvature itself [70, 71]. 
It will then undergo a GTP dependent conformational change [67] leading to the 
constriction of the helix. After constriction, the vesicle needs to detach from the PM. 
How exactly this occurs remains a matter of debate, yet some general hypothesis about 
this process exist. One possibility is that fission is a spontaneous process, facilitated by 
constriction of dynamin and dependent on membrane tension [72, 73] and lipid 
composition [74].  
The last step is the uncoating of the vesicle. This process is mediated by the ATPase 
HSC70 and its cofactor auxilin [75, 76]. It also seems that changes in the lipid 
composition of the vesicle are required for uncoating, as the lipid phosphatase 
synaptojanin is also essential in this process [77]. It will act preferentially on curved 
membranes [78], creating PI(4)P from PI(4,5)P2. This might serve as a recruiting signal 
for auxilin, which binds to PI(4)P [79]and auxilin in turn will recruit HSC70 [80, 81]. 
With uncoating the clathrin coat becomes available again for other nascent pits while the 
new vesicle progresses through the endocytic pathway. 
 
Clathrin-independent endocytosis 
 
Apart from CME, a large number of different pathways into cells exist. Although very 
different from one another, they are grouped under the term clathrin-independent 
endocytosis (CIE).  
 
 
Fig .5 :  Pathways  o f  c la thr in - independent  endocy tos i s  Clathrin-independent endocytosis can to date be 
classified into 5 different routes that are either dynamin-dependent (blue circles) or –independent. All pathways 
eventually converge in the EE, from where cargo is sorted to recycling or to degradation.  
 
For further specification, the pathways are classified as either dynamin-dependent or –
independent and are generally divided into five routes: caveolae, RhoA-, Flotillin-, 
Cdc42- or Arf6-regulated [82] . This list is probably not exhaustive, as novel pathways 
continue to be described, such as fast endophilin-mediated endocytosis (FEME) [83]. 
? 19 
In general the requirements for cargo selection for CIE is not well understood and so far, 
no specific adaptors, such as those found for CME, have been identified for CIE [84]. 
Additionally, it seems that these pathways are at least partly overlapping for some cargo 
proteins and might be highly cell-type and context-dependent [85, 86]. 
In the absence of the classical curvature-generating proteins from CME, it seems that 
CIE (except caveolar endocytocis) has established a general theme with actin as a core 
component for generating pits. Curvature generating proteins on the in- and outside 
could help with clustering receptors and applying bending force to generate stable pits 
without caveolar and clathrin coats [87]. 
  
Caveolae 
 
Caveolae are stable invaginations of the PM containing caveolin, its accessory proteins 
called cavins and that are rich in sphingolipids and cholesterol [88]. Although normally 
stable at the PM [89], caveolae can become endocytosed vesicles when stimulated [90, 
91]. The internalization process of caveolae is dynamin-dependent [92] and in contrast to 
CME, the coat structure is not disassembled after budding [90]. 
Caveolae, apart from being endocytic carriers, seem to be dominantly active in their 
“second life” and are important in PM architecture and signaling [88]. 
 
RhoA-dependent endocytos is  
 
This pathway was initially discovered as the pathway to internalize interleukin 2 (IL-2) 
receptor [93]. It is now also clear that other receptors can make use of this pathway [84, 
94]. As caveolae and CME, it depends on dynamin and also on the presence of lipid rafts 
[93]. 
 
Cdc42-dependent endocytos is  (CLIC/GEEC pathway) 
 
Cdc42, like RhoA, is a small GTPase that regulates this dynamin-independent pathway 
[95]. The most prominent cargoes of this pathway are GPI-anchored proteins [95, 96] 
and it seems to be the major fluid uptake route in cells [97]. The correct functioning of 
the pathway depends on cholesterol and actin [98]. The vesicle carriers of this pathway 
are called clathrin- and dynamin-independent carriers (CLICs) [99] and will mature into 
GPI-AP enriched early endosomal compartments (GEECs) [95] that will eventually fuse 
with early endosomes [100]. 
?
Arf6-dependent endocytos is  
 
This pathway is probably the most cryptic CIE route to date. It is supposed to play a role 
in the internalization of e.g. MHC class I, β1 integrins and GPI-AP [84]. However, it 
might be that it is not necessarily endocytosis but rather recycling that is regulated by this 
small GTPase [101]. Further debate is on the subject if Arf6 depends on dynamin or not, 
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how cell-type variability can be accounted for [84, 85] and if Arf6 and Cdc42-dependent 
pathways are really distinct or might intertwine [82]. 
Flot i l l in-dependent endocytos is  
Flotillin-dependent endocytosis has been described as an additional way for cargo to get 
into cells in a clathrin- and dynamin-independent manner [102]. Flotillins can induce 
curvature of the membrane, circumventing the need for other curvature-inducing and 
stabilizing proteins [103]. Although initially described as not dependent on dynamin,
some studies show a dependency on dynamin [104, 105]. Potentially, flotillins recruit 
specific cargo and target them to other, dynamin-dependent or –independent 
mechanisms. 
Endosomal pathway/endosome maturation 
Fig .6 :  Schemat i c  dep i c t ion  o f  the  g enera l  endocy t i c  pathway After being endocytosed, cargo is 
delivered to early endosomes (EE), from where it can either be recycled back to the PM or can continue by 
maturation on to late endosomes (LE). Finally, LE merge with lysosomes to endolysosomes, which will eventually 
mature to lysosomes. Figure from [106] 
Early endosomes (EE) are the first place cargo encounters after endocytosis and also the 
main sorting compartment of the endocytic pathway [106]. EE are vesicles loosely 
defined by several characteristics: they have a pH of 6.8-5.9, making them slightly acidic 
[107], the presence of Rab5, a small GTPase [108] and the phospholipid PI(3)P [106, 
109] and their structure with both vacuolar and tubular domains. The tubular domains 
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can vary in their membrane composition and their function, linked to their function as 
different sorting regions/vesicle generation hubs [110-112]. The vacuolar part of EE 
seems to be the domain that matures into late endosomes (LE). Generally speaking, 
these LE are more acidic than EE, with a pH ranging from 6.0 to 4.9 [107], Rab5 is 
replaced by Rab7 [108, 113], PI(3)P is converted into PI(3,5)P2 by phosphatidylinositol 3-
phosphate 5-kinase (PIKfyve) [114-116] and the lumen of LE contains a large number of 
intraluminal vesicles (ILV). LE will fuse with lysosomes, creating endolysosomes, where 
most of the degradation processes take part.  
But the default pathway for cargo arriving in EE is not degradation but rather recycling. 
In this case, receptors will traffic to EE and will be retargeted to the PM via recycling 
endosomes. To be selected for degradation, receptors seemingly need to display a 
characteristic signal, otherwise they will follow the bulk back to the surface [117].   
The maturation from EE to LE can be described by different, intertwining and 
interdependent processes taking part. The first one is the so-called Rab switch, where 
different Rab proteins present on EE will be exchanged by others during maturation. 
Especially Rab5 and Rab7 have been described as master regulators of endosome 
maturation. On EE, Rab5 and many of its effector proteins are present, giving the 
compartment its identity [108, 109]. One of the effectors is the VPS34/p150 complex, 
which is a PI kinase complex and produces the EE signature lipid PI(3)P [118, 119]. To 
mature into LE, Rab5 is replaced by Rab7 [113, 120]. This switch also changes the 
recruitment of accessory proteins, modifying the identity of the vesicle and e.g. ensuring 
that the maturing endosomes will only fuse with downstream vesicles such as other LE 
or lysosomes, thereby securing the unidirectionality of the pathway [121].  
Vesicles in the endocytic pathway also have their own specific lipid “fingerprint” which 
changes during maturation with PI(3)P being the prominent lipid for early and PI(3,5)P2 
for late endosomes. These lipids in turn recruit specific subsets of effector proteins that 
bind to their destination vesicle via PI-binding domains, such as FYVE, PH, PX, PHOX 
and BAR [122, 123]. Among these effector proteins are also PI kinases, thereby 
regulating local generation of the necessary PI species. An example is the generation of 
PI(3,5)P2 by PIKfyve, which will bind to PI(3)P rich membranes, i.e. membranes of EE 
with its FYVE domain, generate PI(3,5)P2 and thereby contribute to the maturation to 
LE [115, 116, 124] . 
Other markers of endosome maturation include change in size and appearance, the 
ability to communicate with the PM via recycling is lost, change in intracellular 
localization, changes in ion composition and different associated proteins and the 
formation of ILV [106] . The presence of ILV characterizes the appearance of LE, which 
are therefore also termed multivesicular bodies (MVB). 
 
ESCRT system and ubiquitin-dependent sorting 
 
Formation of ILV can already appear in EE [125] and is mediated by the endosomal 
sorting complex required for transport (ESCRT) [126-130]. The ESCRT system consists 
of five complexes that take part in the different processes during cargo selection for 
degradation, bud formation and membrane scission [131]. The ESCRT complex plays 
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also a role in other cellular processes such as autophagy and cytokinesis [132], yet this 
will not be discussed here. 
Table  1 :   Lis t  o f  pro t e in  components  o f  the  ESCRT complexes  in  bo th  yeas t  and human 
f rom [133] 
In early endosomes, cargo that has entered the endocytic pathway needs to be separated 
into a pool that will go back to its original localization via recycling and a pool that is 
destined for degradation. With recycling being the default pathway, sorting to the 
degradative system needs to be mediated by a signal. This signal is mostly the
ubiquitination of target proteins [134]. 
Ubiquitination is a posttranslational modification that consists of the attachment of the 
76 amino acid peptide ubiquitin to lysine residues of target proteins [135]. Ubiquitination 
controls a plethora of cellular processes, similar to phosphorylation, yet ubiquitination 
tops phosphorylation in terms of complexity as ubiquitin can itself be ubiquitinated, 
leading to complicated chains and linkages. 
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Fig .7 :  Enzymat i c  r ea c t ion  o f  ub iqui t inat ion and d i f f e r en t  l inkages  A) Shown is the enzymatic, 
ATP-dependent cascasde, leading to the ubiquitination of the target protein. E1 ubiquitin-activating enzyme 
acquires an Ub moiety and passes it on to E2 ubiquitin-conjugating enzymes. From there it will go to members of 
either the RING or HECT family of E3 ligases, which will eventually pass it on to the substrate. B) Structure of 
the ubiquitin protein with its lysines and the consequences of the different linkages on the fate of the ubiquitinated 
protein. Image from [136] 
The attachment of ubiquitin is an ATP-dependent three-step process, mediated by E1 
ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes and E3 ubiquitin ligases 
[137] (Fig.7A).  There are only two E1 and 37 E2 enzymes but over 600 E3 ligases [135]. 
The ubiquitin is attached by its C-terminal glycine residue to lysines of the target protein 
by the E3 ligases. Ubiquitin itself contains 7 lysines (K6, K11, K27, K29, K33, K48 and 
K63) which themselves can be ubiquitinated. The linkage and length of the ubiquitin 
modification determine the fate of the modified protein. Additionally, it has been 
recently reported that ubiquitin can be phosphorylated on Ser65, adding an additional 
layer of regulation [138]. Ubiquitination is a reversible modification and the breakdown 
of ubiqutitin chains is mediated by enzymes called deubiquitinases (DUBs) [139]. 
Although it is not clear, what effect exactly every possible ubiquitination pattern will 
have, some “canonical” patterns have been studied quite extensively. The most famous is 
the K48 polyubiquitin chain, a signal for proteasomal degradation [140]. The ubiquitin 
signal for endocytosis was long believed to be only monoubiquitination, but also K63 
linked chains have been reported to control this process [141-143]. Other processes that 
ubiquitin controls range from DNA repair, gene expression, to autophagy and virus 
budding (Fig.7B). 
Proteins can be ubiquitinated in a variety of different patterns. The pattern associated 
with targeting to ILV seems to be primarily K63-linked ubiquitination, either in form of 
poly-, mono- or multimono-ubiquitin chains [134]. The ubiquitinated cargo is bound by 
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the ESCRT complexes, which contain ubiquitin-binding motifs and is then handed over 
to the next complex in line [131, 133, 134].   
Fig .8 :  Depi c t ion  o f  the  a c t ions  o f  ESCRT complexes  Shown is the movement and deformation of the 
membrane, the different ESCRT complexes associated at each step and the consequences for the protein cargo. 
Image from [144] 
The first to encounter ubiquitinated cargo is the ESCRT-0 complex. In mammalian cells, 
ESCRT-0 consists of Hrs and STAM1/2 [129, 130] and will, in addition to ubiquitin, also 
bind to PI(3)P via the FYVE domain of Hrs, thereby ensuring faithful localization to 
early endosomes [145]. STAM contains a SH3 domain, which will recruit and interact 
with two deubiquitinating enzymes:  AMSH and USP8 (UBPY) [146, 147]. By modifying 
the ubiquitination of proteins, these two proteins can affect the fate of cargo that 
associates with ESCRT-0. Depending on the type of modification and also on the 
protein, cargo will either by sent to recycling or to degradation following 
deubiquitination by AMSH and USP8 [148]. USP8, in addition to modifying cargo, also 
seems to stabilize Hrs and STAM2, thereby contributing to normal functioning and 
morphology of endosomes [149, 150]. 
ESCRT-0 has now clustered cargo together and then mediates recruitment of ESCRT-I 
to endosomes [151, 152], thereby conveniently ensuring the handover to the next 
complex. ESCRT-I also binds to ESCRT-II, forming a supercomplex that is important 
for the budding of the membrane in ILV formation [153]. ESCRT-II will then recruit 
ESCRT-III, which will finally act on pinching off the membrane and thereby finalizing 
the process of a successful ILV formation [154]. For the disassembly of ESCRT-III, the 
last complex, Vps4-Vta1 is needed [155]. Vps4 is an AAA ATPase and associates with 
Vta, forming a complex that will render the membrane-bound ESCRT-III complex 
soluble again, ready for a new cycle [144]. 
Endocytosis and signaling  
The link between endocytosis and signaling has usually been the notion that after 
endocytosis, the signal of e.g. receptor tyrosine kinases is stopped, given that they are 
sequestered from the PM and degraded. But more recently, increasing attention has been 
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given to the fact that these two processes seem to be intimately linked and that 
endocytosis can control signaling but also vice versa [156].  
First, endocytosis can indeed attenuate signaling by changing the amount or the 
localization of receptors at the surface. Attenuation of the signal can also be achieved by 
physically separating the ligand from the receptor e.g. by a change of lipid species, which 
differs between PM and endosomes [157]. On the other hand, signaling can continue 
from endosomes e.g. for EGFR or GPCR [158, 159] or might exclusively be restricted to 
endosomes, such as in some signaling cascades of the TGFβ receptor [160]. Where 
signaling occurs might affect the outcome and change the proteins that are activated 
downstream [161] but also how receptors enter the cell influences their signaling [162]. 
Signaling can also have an impact on endocytosis. Studies on the EGFR show that 
activation of the receptor by its ligand can increase clathrin coated pit formation through 
the downstream activation Src kinase, thereby increasing its uptake [163, 164]. Other 
impacts are e.g. on the speed of endocytosis [165] or on the morphology of the pathway 
[166], thereby showing that cargo itself can tweak its entry route.   
 
Pathogen entry 
 
Many pathogenic agents, such as viruses, bacteria or toxins need to get into their host cell 
to replicate or to exert their function. Therefore, the easiest way in is to hijack already 
existing pathways and potentially even customize them for the respective needs.  
 
Viruses and endocytos is  
 
For viruses, entering cells by endocytosis is not only an easy way in but also comes with 
several other advantages. Endocytosis delivers viruses through the cytoplasm close to the 
nucleus, thereby avoiding the path through the cytoplasm. The identity of the maturing 
endocytic vesicles helps the virus to determine its localization in the cell and the change 
in pH can provide an important cue for uncoating and penetration [167, 168]. Other 
proteins, such as proteases present in endosomes can help activate viral particles [169, 
170] and finally, entry through endosomes hides the virus as it leaves no trace at the PM, 
thereby probably helping immune avoidance [171, 172]. There are viruses such as HIV-1 
that can establish a successful infection both by entering the cell via endocytosis and by 
fusion with the PM [173, 174], but the majority of viruses depend on at least a part of the 
endocytic machinery for an efficient entry [172]. Generally speaking, viruses can exploit 
any given endocytic pathway, from CME, caveolae and also CIE or even completely 
novel pathways [175, 176]. They might even manipulate the speed of uptake by invoking 
formation of CCP, such as influenza virus [177] or stimulate CME for increased 
cholesterol trafficking to create favorable replication conditions, such as enteroviruses 
[178]. All this has made viruses a favorite for deciphering intracellular trafficking 
pathways for decades and more recently, also a promising approach for intracellular 
delivery of drugs and proteins [179, 180]. 
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Bacter ia and endocytos is  
 
Bacteria as an endocytic cargo are extremely large, ranging typically between 1-5 μm. 
This means that classical pathways, as described earlier cannot be applied here. In 
general, bacteria are taken up into cells by an-actin dependent reorganization of the PM, 
either by a so-called zipper or trigger mechanism [172]. For the zipper mechanism, some 
bacteria such as Listeria monocytogenes or uropathogenic Escherichia coli will bind to 
receptors at the PM, trigger recruitment of clathrin and potentially other factors and 
leads to actin rearrangement, ultimately engulfing the bacteria [181, 182]. It seems that 
clathrin serves as a cellular platform from which activation of internalization can be 
initiated instead of its canonical role. 
The trigger mechanism is used e.g. by Shigella and Salmonella to enter cells. Here, the 
bacteria actively initiate uptake by injecting effector proteins into the cell, which will 
induce extensive rearrangements of the actin cytoskeleton and formation of ruffles which 
will eventually envelope the bacteria [172].  
Once inside the cell, bacteria by all means need to avoid reaching the lysosome. The 
tactics to do this reach from perforating and destroying the endosomes by secreted 
toxins or by blocking maturation by different means [183]. 
 
Toxins and endocytos is  
 
Protein toxins, such as botulinum, tetanus, Shiga, anthrax or ricin toxins also make use of 
the various entry routes to gain access into their target cells. In fact, the notion of 
clathrin-independent endocytosis originally stems from the observation that ricin, a plant 
toxin, can enter cells even in the absence of clathrin [184]. The classical entry route of 
toxins is that they will bind to their receptor at the PM and will then enter the cell either 
via clathrin-dependent or –independent mechanisms. Sometimes this is not exclusive: 
some toxins have been reported to enter via several pathways, such as Shiga toxin, which 
can enter by several mechanisms, despite binding exclusively to one receptor [185]. The 
same is true for cholera toxin [186]. Toxins are also excellent in modifying their own 
uptake. Shiga toxin will reorganize lipids on the PM to maximize uptake [187] or will 
increase the formation of CCP via the tyrosine kinase Syk [188]. Like viruses, toxins have 
been used extensively in studying endocytosis and are a promising approach for 
intracellular targeting of drugs. There is even an approved immunotoxin consisting of a 
fusion of diphtheria toxin and IL2, which is used in T-cell lymphoma [185]. 
 
Anthrax toxin endocytos is 
 
Anthrax is an infectious disease that is caused mainly by the exotoxins of the Gram-
positive, spore-forming bacteria Bacillus anthracis. B. anthracis is a member of the Bacillus 
family and is commonly found in soil. The animals that are most commonly affected 
with anthrax are herbivores and infection can occur worldwide, although cases are rare 
and only sporadic [189, 190].  
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Anthrax has received a large amount of attention after the bioterrorism attacks of 2001 
in the US. Weaponized, i.e. easily inhalable anthrax spore preparations led to 22 cases of 
anthrax of which 11 were fatal. In an earlier incident in 1979 in Russia where there was 
an unintentional release of anthrax spores, 77 cases were diagnosed of which 66 were 
fatal [190]. 
Anthrax is acquired by spores entering the body, either through a lesion, by inhalation or 
ingestion. Cutaneous anthrax, which is when anthrax spores enter the body through a 
skin lesion, is the most common but also the most treatable form of anthrax. If spores 
are inhaled or ingested, the disease is much more difficult to manage. For cutaneous 
anthrax, localized tissue edema and necrosis lead to a black eschar at the lesion site, a 
very distinct feature of anthrax. Gastrointestinal and inhalation anthrax present 
themselves with very non-specific symptoms and then in the acute phase will develop 
high fever, toxaemia and sepsis, which can be fatal [189, 191]. 
One of the main virulence factors of B.anthracis is the anthrax toxin. The anthrax toxin is 
a tripartite AB toxin with the three subunits Protective Antigen (PA), Edema Factor (EF) 
and Lethal Factor (LF). PA is the receptor-binding subunit, whereas EF and LF are the 
enzymatic subunits of the toxin. All the toxins are encoded on the virulence plasmid 
pXO1 [192]. 
 
Fig .9 :  Entry  o f  anthrax toxin in to  targe t  c e l l s .  B.anthracis secretes 3 subunits of the anthrax toxin: 
protective antigen (PA), edema factor (EF) and lethal factor (LF). PA will bind to either of the anthrax toxin 
receptors, CMG2 or TEM8, will be cleaved by furin and then heptamerize in lipid rafts. There it can bind the 
enzymatic subunits EF and LF and subsequently internalize. In the endosome, the heptamer will insert into the 
membrane, form a translocation pore and allow dislocation of EF and LF to the cytoplasm. EF elevates cytosolic 
cAMP levels and LF cleaves MEKs, thereby leading to edema and necrosis. 
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All three toxin subunits are secreted by the bacteria and as a first step, PA83, the 83kDa 
form of PA will bind to the vWA domain of one of the two anthrax toxin receptors on 
the target cell, CMG2 or TEM8. The main anthrax toxin receptor in vivo is CMG2 [193]. 
This might be partially due to a higher affinity of PA for CMG2, which ranges from 
1000-fold for purified vWA domains [194] to only about 11-fold in cell culture 
experiments [193]. As PA83 is unable to interact with EF or LF, the toxin has to be 
modified. Therefore, after binding to the receptor, the toxin will be cleaved by furin, 
which will produce PA63 [195, 196]. The cleavage recognition site on PA is Arg-X-X-Arg, 
which when changed to Pro-Gly-Gly, cannot be cleaved, thereby rendering the toxin 
unable to proceed after binding to the receptor [197]. After this step the receptor-toxin 
complex multimerizes, either into heptamers or octamers [198, 199]. Up to 3 subunits of 
either LF or EF can then bind to the complex. These multimers then partition into 
specific nanodomains of the plasma membrane, so-called lipid rafts [200]. The binding 
and heptamerization leads to the activation of Src-like kinases, which can then 
phosphorylate the receptor on its cytoplasmic tail [201]. This phosphorylation is a 
prerequisite for ubiquitination, which is important for endocytosis [201, 202]. TEM8 is 
ubiquitinated by Cbl, the E3 ligase of CMG2 so far remains unknown [202]. Another 
protein that is involved at this phase is?-Arrestin, an adaptor protein in CME [29]. 
Anthrax toxin endocytosis is a clathrin-dependent process [29] although it might also be 
able to use alternative routes [203]. Actin also plays a role in the endocytosis of both 
receptors. It pre-organizes TEM8 in clusters at the PM and then is important in the 
internalization of both receptors in a toxin-bound state [29].  Once inside the endocytic 
pathway, the heptamer will at one point insert into the membrane and form a pore that 
will allow LF and EF to translocate to the other side. This translocation is proton-
gradient driven [204] and follows the model of a Brownian-ratchet model [205]. To pass 
through the narrow PA channel, LF and EF partially unfold in the acidic environment of 
the endosome [206]. LF and EF can act on their targets in the cytoplasm. LF is a zinc-
dependent metalloproteinase. It cleaves MEKs, which are MAP kinase kinases and have 
a vast inhibitory effect on diverse cellular pathways [207]. EF is a calmodulin-dependent 
adenylyl cyclase, which leads to the increase of cAMP, a second messenger impacting on 
a variety of cellular functions [191]. Whether this translocation occurs at the early or late 
endosome, depends on the receptor the toxin is bound to. TEM8-bound PA will insert 
already at early endosomes, CMG2-bound PA only at late endosomes [208]. 
Translocation of EF and LF seems to occur across the PA pore into the lumen of ILV. 
Release of the enzymatic subunit to the cytoplasm can then occur by backfusion of these 
ILVs with the limiting membrane [209]. The ILVs can however also eventually be 
released as exosomes and transmit the enzymatic toxin subunits to naïve cells, 
circumventing receptor usage, thereby acting as a long-term and long-range transmitter 
for anthrax toxin [210]. 
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3. Partner proteins of CMG2 
?
To study the physiological function of CMG2 more in detail, several potential partner 
proteins were identified by either Yeast 2 Hybrid screens or proteomic studies. Here, the 
four proteins studied during this thesis are rapidly introduced. 
MARK2 
 
The microtubule-affinity regulating kinases (MARK) or Par-1 kinases are part of the 
AMPK/Snf1 subfamily of the Ca2+-calmodulin-dependent protein kinases (CaMK) [211]. 
In mammals we can find MARK1-4 (corresponding to Par1c, b, a, d) and each isoform 
can occur in different splice forms [212]. As the name implies, MARKs were initially 
identified as regulators of microtubule dynamics by means of phosphorylating 
microtubule-associated proteins (MAPs) [211]. Yet over the years it has become clear 
that they are also involved in several other key cellular processes such as establishment of 
cell polarity, neuronal differentiation, intracellular trafficking, cell migration and 
neurodegeneration [213]. 
MARK2 (Par1b) has been extensively described in the establishment of polarity in 
various mammalian cells. MARK2 is a downstream target of aPKC, another kinase 
master regulator of cell polarity and is involved in the establishment of asymmetric 
membrane domains [214, 215]. aPKC phosphorylates a threonine residue (T508 for 
isoform 3) which antagonizes MARK2 activity. The phosphorylation promotes binding 
to 14-3-3 proteins, sequesters MARK2 away from the basolateral membrane, where it is 
usually found and acts negatively on its kinase activity [214, 215].  
MARK2 controls polarity by acting on the microtubule cytoskeleton [216] but also 
regulates the RhoA-dependent rearrangements of the actin cytoskeleton [217]. The 
effects of MARK2 on the cytoskeleton are also apparent in cells infected with Helicobacter 
pylori. CagA, a virulence factor of H.pylori, associates with and inhibits MARK2 [218]. 
CagA activity leads to cells with an elongated shape, causing the so-called hummingbird 
phenotype. This phenotype partly depends on stabilization of microtubules, breakdown 
of focal adhesions and activation of myosin II, all of which are regulated by MARK2. By 
inhibiting MARK2, CagA ensures an efficient breakdown in polarity and the 
establishment of the hummingbird phenotype [219]. 
Another way of establishing polarity for MARK2 is by communicating with the ECM 
[220, 221]. Rho kinase (ROCK) ensures basolateral positioning of MARK2 in mouse 
epithelium, which in turn controls the correct spatial deposition of basement membrane 
[221]. Almost the same is true in MDCK cells, where MARK2 regulates the localization 
of the dystroglycan complex to the basolateral side, which is a spatial cue for deposition 
of laminin, a member of the basement membrane [222]. Also in MDCK cells, MARK2 
controls the actin organization as well as the cell-ECM matrix communications by 
regulating the scaffolding protein IRSp53 [220].  
MARK2 contributes to the establishment of polarization by affecting polarized 
trafficking [223, 224]. It was also shown that MARK2 can interact with AP-2, thereby 
associating with CCVs [225]. 
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Interestingly, as for CMG2, MARK2 has repeatedly been associated with the Wnt 
signaling pathway. In Drosophila, Xenopus and in mammalian cells MARK2 potentiates 
Wnt signaling and treating cells with Wnt vice versa increases MARK2 activity [226]. 
MARK2 phosphorylates Dishevelled, which leads to a downstream β-catenin 
stabilization in the canonical Wnt pathway [226]. This regulation is important during 
different steps of development and might be mediated by different isoforms [227]. 
MARK2 also seems to be a link between the TGFβ pathway and the non-canonical Wnt 
pathway. MARK2, Dishevelled and SMAD4 form a complex upon Wnt5a stimulation, 
mediating crosstalk between the two pathways [228]. 
 
RNF41 
 
RNF41 (Nrdp1/FLRF) is an E3 ligase, which was first found to control trafficking of 
neuregulin receptors ErbB3 and ErbB4 [229]. It is ubiquitiously expressed with a higher 
signal in brain, heart and skeletal muscle cells [229] and also in prostate, ovary and testes 
[230]. RNF41 ubiquitinates ErbB3 and promotes its degradation, independent if ligand is 
bound or not [229, 230]. RNF41 also autoubiquitinates itself, which leads to its 
degradation by the proteasome, thereby making the protein in cells very unstable [229, 
230]. This autoubiquitination requires oligomerization of RNF41, which is dispensable 
for ubiquitination of its substrates [231]. RNF41 can be stabilized by the DUB USP8, 
which removes the ubiquitin moiety from RNF41 [232]. Interestingly, it seems as if 
USP8 is stabilized in response to ligand binding of the ErbB receptors and this in turn 
stabilizes RNF41, ultimately leading to a downregulation of the pathway [233].  
The regulation of the two proteins might be both ways, as RNF41 was also shown to 
ubiquitinate USP8, induce its degradation and thereby also affect stability of the ESCRT-
0 complex [234].  
RNF41 also regulates degradation of other receptors or proteins, such as parkin [235], 
cytokine receptors [236] and MyD88 [237]. For some proteins, interaction with RNF41 
actually targets them away from degradation, potentially by rerouting them to other 
compartments [238]. 
In addition to a role in trafficking and degradation, RNF41 has also been linked to 
polarity. A proteomic study suggests that RNF41 might be the missing mammalian 
orthologue of Par2, a protein involved in polarity in C.elegans and Drosophila [239]. Par2 
interacts with Par1, where the mammalian homologues are members of the MARK 
family, such as MARK2. In another study, RNF41 was found to be a novel MARK2 
effector in establishing cell polarity in mammalian epithelia cells [240]. MARK2 
phosphorylates RNF41 at S254 and this in turn is important for the correct positioning 
of laminin receptor to the basolateral side and subsequent correct deposition of the 
basement membrane protein laminin [240]. This study also considers the idea of RNF41 
being functionally orthologous to Par2.  
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USP8 
 
The deubiquitinating enzyme USP8 (UBPY) was first discovered to be associated with 
the ESCRT-0 complex [147]. Hrs and STAM, the two ESCRT-0 complex members are 
linked to two DUBs, namely AMSH and USP8. In the absence of USP8, ubiquitinated 
proteins accumulate on endosomes, including components of the ESCRT complex, and 
MVBs tend to accumulate [149, 241]. Depletion of USP8 in vivo is embryonic lethal and 
even a conditional knockout in adult mice results in liver failure [150]. Again, endosomes 
display an abnormal enlarged phenotype, which is accompanied by gradual loss of several 
growth factor receptors and the ESCRT-0 complex [150].  
Several receptors or more specifically their trafficking has been shown to be regulated by 
USP8. CXCR4, a chemokine receptor is stabilized in the absence of USP8 and 
accumulates at the early endosome [242]. Activated receptor tyrosine kinases, such as 
EGFR and met, are also stabilized in the absence of USP8 [241]. But, especially for 
EGFR, there is conflicting data on the effect of USP8. USP8 was shown to drive EGFR 
degradation by promoting sorting into MVBs after being activated by Src [243-245]. 
Other studies claim that USP8 rescues EGFR from degradation by targeting it to 
recycling rather then to the degradative pathway [149, 246]. So far it is unclear, which 
scenario is correct or whether the observed effects are context-dependent. 
As described earlier, USP8 and RNF41 seem to be in the same pathway. They cross-
regulate each other, thereby impacting on the decision if a receptor is sent to recycling or 
degradation [234].   
Very recently, mutations in USP8 were found to cause Cushing’s disease [247-249], 
which is the overexpression of cortisol from the pituitary, most often as a result from a 
pituitary adenoma. The mutations that were identified are gain of function mutations 
located in exon 14, located around the 14-3-3 binding motif. USP8 can no longer bind to 
14-3-3, thereby showing increased DUB activity. They target EGFR to recycling, 
prolonging its signaling after receptor activation [249]. 
Cbl 
 
Cbl (Casitas B-lineage Lymphoma) is also an E3 ubiquitin ligase of a highly conserved 
family that has homologues in Drosophila, C.elegans and even Dictyostelium discoideum. 
Initially, Cbl was found as v-Cbl, what is now known to be a viral oncogene in murine 
leukemia virus [250]. The cellular homologue c-Cbl or Cbl is actually a longer form of 
this truncated version and is implicated in various cellular processes, in particular in the 
regulation of receptor tyrosine kinase (RTK) trafficking [251, 252]. 
The consensus is that ubiquitination of cell surface receptors ultimately promotes their 
lysosomal degradation [253]. However, at what step exactly Cbl acts on the receptor after 
ligand binding remains a controversial subject. Cbl can directly ubiquitinate receptors, 
which could mediate the first step of internalization [254].  This view has been 
challenged, suggesting that ubiquitination of EGFR is important for sorting to 
degradation but not for endocytosis [255]. Also, the role of Cbl in endocytosis might be 
independent from its role as an E3 ligase but might be more linked to its function as an 
adaptor protein. Cbl contains a Tyrosine Kinase Binding (TKB) domain, which can bind 
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to phosphorylated tyrosines in specific peptides of protein tyrosine kinases, such as 
EGFR, Src/Fyn or ZAP70. It also has a C-terminal proline rich region that can bind 
SH3-domain containing proteins such as CIN85, Grb2 or again Src/Fyn [253]. This 
makes it a perfect adaptor protein. After ligand binding to the EGFR, Cbl becomes 
activated and can recruit CIN85. This leads to the formation of a large complex of 
proteins required for endocytosis, such as curvature-inducing endophilins, synaptojanin, 
which acts on membrane lipid composition or ARAP3, a protein linked to cytoskeletal 
rearrangements [256-258]. Interestingly, ARAP3 has been shown to be important for 
anthrax toxin entry as well [259]. Therefore, Cbl might act directly and indirectly on 
endocytosis of cell surface receptors, determining their fate at different steps of the 
endocytosis process. 
 
Note: This introduction contains parts of a review manuscript in preparation.  
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4. Glycosylation and ERQC/ERAD 
 
Glycosylation 
 
Posttranslational modifications of proteins are important for and modulate a variety of 
functions in proteins. Attaching e.g. phosphate groups, lipid moieties or glycan 
sidechains can change the properties of a protein and subsequently its functions and 
activity. Glycosylation is one of the most common protein modifications and 
bioinformatics estimate that more than 50% of eukaryotic proteins are glycosylated [260].  
The process of glycosylation is conserved between eukaryotes and prokaryotes [261] and 
glycosylation is implicated in various cellular processes such as protein folding, stability, 
trafficking, localization, endocytosis, interactions and adhesion [262-264]. There are five 
types of glycosylation: N-, C-, O- and P-glycosylation as well as glypiation, with N-
glycosylation being the most common one [265]. N-glycosylation consists of two steps: 
the attachment of a core oligosaccharide to the asparagine residue of the N-X-S/T 
consensus sequence (where X is any amino acid except proline) and initial trimming in 
the ER followed by additional trimming and extension of the glycan sidechains in the 
Golgi [266, 267]. The core oligosaccharide, which is co-translationally attached to the 
asparagine residue of transmembrane and secreted proteins by the 
oligosaccharyltransferase (OST) consists of Glc3Man9GlcNAc2 (Glc: glucose, Man: 
mannose, GlcNAc: N-acetylglucosamine). The building blocks of the chains consist of 
ten monosaccharides: Glc, Man, GlcNAc, Fuc (fucose), Gal (galactose), GalNAc (N-
galactosamine), GlcA (glucuronic acid), IdoA (iduronic acid), SA (sialic acid) and Xyl 
(xylose). The estimates of possible glycan sidechains in the human glycome come up with 
a number of around 7000, highlighting the diversity that glycosylation can confer to its 
protein substrate [268]. 
 
N-glycosylation and protein folding 
 
Although N-glycosylation affects various processes, its best characterized role is in 
protein folding. Before being shuttled to their final destination in the cell and becoming 
active, proteins need to fold correctly. For membrane and secreted proteins, folding 
occurs in the ER and generally with the help of ER-resident chaperones. These proteins 
need to distinguish between newly synthesized and terminally misfolded proteins in the 
densely packed ER and therefore decide their fate. This is a tricky task and N-
glycosylation has been proposed to be both advantageous for folding [269] and also to 
help the ER quality control machinery to distinguish these two protein groups [270].  
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Fig .10:  Scheme o f  N-g ly cosy la t ion  in  the  ER and i t s  ro l e  in  ER qual i t y  contro l  and ER 
asso c ia t ed  degradat ion  In short: proteins are co-translationally glycosylated with the core oligosaccharide, 
transferred to the acceptor sequence by the OST. After initial trimming of the two outermost glucose residues, the 
protein is prone to interact with the ER resident chaperones calnexin or calreticulin. If the protein folds correctly, 
the last glucose residue is trimmed and the protein is transported to its final destination via the Golgi complex. If 
folding is unsuccessful, the protein will be targeted to ER associated degradation (ERAD) by ER quality control 
(ERQC). The glycan sidechain is extensively trimmed to its mannose residues, which then acts as a targeting 
signal for ERAD. The terminally misfolded proteins are retrotranslocated out of the ER and degraded by the 
proteasome. Figure from [264] 
Proteins are co-translationally glycosylated during their entry into the ER by the 
oligosaccaryl transferase (OST) [267, 271] and the first glucose residue is immediately 
trimmed by α-glucosidase I. This di-glycosylated protein species was long believed to be 
only an intermediate. Recently, malectin, an ER-resident lectin specifically binding these 
proteins, was discovered [272]. It seems that already at this step, malectin can recognize 
misfolded proteins and target them for degradation [273-275]. The second trimming of a 
glucose residue, this time by α-glucosidase II, leads to the association of the protein with 
either calnexin or calreticulin. Calnexin and calreticulin are ER-resident lectins, sharing
both structural as well as binding similarities: they both bind to monoglycosylated 
oligomannose glycans in a calcium-dependent manner [276]. Calnexin, itself a 
transmembrane protein, can bind both soluble as well as transmembrane proteins. 
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Calreticulin, which is soluble, can also bind both types but seems to prefer soluble 
substrates [270]. It was initially thought that both calnexin and calreticulin were specific 
for glycosylated proteins, but more recent works suggests that they can also assist the 
folding of non-glycosylated substrates by binding to peptide regions instead of the glycan 
sidechain [277, 278]. Nevertheless, both proteins are essential for the correct functioning 
of cells, as knockout mice for either calreticulin or calnexin either are embryonic lethal 
for calreticulin or are born with strong motor disorders for calnexin, with only very few 
mice surviving past 48h after birth [279, 280].  
While interacting with either calnexin or calreticulin, proteins try to fold correctly. The 
third and last glucose residue can be removed by α-glucosidase II, which is the enzyme 
already responsible for the removal of the second glucose residue. In contrast to the first 
reaction, removal of the last glucose residue decreases the association of the protein with 
the chaperone, thereby releasing it. From here, there are two possible fates of the 
protein, depending on its folding state: 
 
1) The protein is correctly folded 
 
In this case, the protein exits the ER via COP II vesicles towards the Golgi apparatus 
[281]. Here, the glycan sidechain undergoes further trimming and extensions. These 
modifications are mediated by a plethora of glycosidases, glycosyltransferases and other 
glycan processing enzymes that are organized in the Golgi in a cis-to-trans fashion [282]. 
Through all these modifications, the proteins can achieve a high degree of complexity in 
their glycan structure. Additionally, several intrinsic characteristics of the Golgi 
contribute to the diversity. First, trafficking of the enzymes but also the substrates in the 
Golgi makes the glycan processing a dynamic and competitive process, with the result 
that even a single site on a protein might be modified differently. Second, the pH of the 
Golgi has been shown to modify efficiency of glycosylation reactions [283] and lastly, the 
presence and correct functioning of the conserved oligomeric Golgi (COG) complex is 
crucial for correct glycan modifications to occur [284, 285]. 
After traversing the Golgi and having gone through all the modification steps, the 
proteins will be routed to their final destination in or outside the cell. 
 
2) The protein is not correctly folded 
 
In this case, the protein is recognized and will be reglucosylated by UDP-
Glc:glycoprotein glucosyltransferase (UGGT1), which in turn leads to re-association with 
calnexin or calreticulin [286, 287]. Subsequent cycles of α-glucosidase II and UGGT1 
action give the misfolded protein several chances to finally achieve a native 
conformation. If this fails, the terminally misfolded protein needs to be removed from 
the ER, as accumulation of misfolded proteins in the ER would lead to ER stress and 
damage the cell. The misfolded protein will be recognized by ER quality control (ERQC) 
and will be then targeted to ER associated degradation (ERAD). 
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Fig .11:  Scheme o f  the  d i f f e r en t  s t eps  o f  ER-asso c ia t ed  degradat ion (ERAD) Proteins that are 
terminally misfolded or not correctly assembled will be recognized by ERQC and targeted for degradation. After 
retrotranslocation to the cytoplasm through a still unknown channel, the protein will be sent to the proteasome and 
will be degraded. Figure from [288]. 
 
After several futile folding attempts and thus a prolonged residence time in the ER, 
misfolded proteins are recognized and tagged for degradation. To do so, ER-resident 
mannosidases will extensively trim the glycan sidechain, generating a tag for ERAD [289-
291]. The mannose residues are recognized by ER lectins OS-9 and XTP3-B [292-295]. 
For non-glycosylated proteins, ERAD targets also seem to be processed by the same 
proteins, although in this case they seem to be recognized by BiP and GRP94 [296, 297]. 
Degradation of ERAD substrates occurs in the cytosol by the proteasome. Therefore, a 
retrotranslocation step is required to deliver the proteins from the ER to the cytosol. 
Although extensive research in this field has been going on for years, the exact nature of 
the retrotranslocation channel is still elusive. Several candidates involve Sec61, several E3 
ligases, members of the Derlin family and others, as reviewed in e.g. [288, 298, 299]. 
Retrotranslocation in most cases is an ubiquitination-dependent step. Substrates are 
ubiquitinated on the cytoplasmic side and are then extracted from the membrane. This 
action is either performed by the proteasome directly [300, 301] or by the Cdc48 
complex [302]. In mammals, this complex consists of the AAA ATPase p97 and the two 
cofactors UFD1 and NPL4. After extracting the ERAD substrate to the cytosol, the 
Cdc48 complex hands it over for degradation to the proteasome, potentially with the 
help of additional proteins [303]. The glycan sidechains are removed by a glycanase [304-
306] and the substrate might be deubiquitinated before entering the proteasome [288]. 
 
The amount of misfolded proteins varies greatly and depends on factors such as folding 
rate, enzyme availability and metabolic state of the cell but also differs for any given 
protein. This means that even under ideal conditions, certain proteins will be degraded 
and the efficiency of protein can be rather low [307, 308]. For notoriously bad folder 
such as CFTR, only around 25% of even wildtype proteins under the best conditions will 
make it past the ER [309], whereas other proteins such as α1AT can attain efficiencies 
up to 90% [293]. This means that ERQC and ERAD are processes that have to be 
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extremely well tuned. Too efficient or too weak ERQC will lead to pathological 
phenotypes, either by degrading proteins too fast or by an accumulation of un-
/misfolded proteins. Therefore, their activity is regulated by ERAD tuning. This model is 
based on the segregation and selective degradation of ERAD factors, thereby modulating 
the efficiency of the whole process [310]. 
Also, ERQC factors need a reliable way to recognize terminally misfolded proteins and 
to distinguish them from folding intermediates. Both protein species share similarities by 
exposing hydrophobic patches, which in a correctly folded protein would not be 
accessible [288, 299]. For unassembled subunits of oligomeric complexes, which are also 
considered ERAD substrates, it seems that the exposure of unshielded, charged residues 
in the transmembrane domain serve as a degron sequence [311-313]. 
 
As most of the conserved cellular pathways, the ERAD pathway can and will be hijacked 
by pathogenic agents. Bacterial toxins such as cholera toxin, Shiga and Shiga-like toxin 
but also the plant toxin ricin utilize ERAD to get from the ER to the cytosol [314]. 
Hijacking ERQC and ERAD was also shown for Simian Virus 40 (SV40) and mouse 
polyomavirus, both trafficking from endosomes to the ER and from there to the cytosol 
and eventually the nucleus [315, 316]. Other viruses modify ERAD for their advantage. 
Human cytomegalovirus infection leads to the degradation of MHC class I and II 
receptors with the help of ERAD factors, thereby dampening the immune response [317, 
318]. HIV can downregulate the expression of its cell surface receptor CD4 by inducing 
the proteasome-mediated degradation of CD4 [319]. Hepatitis virus B and C in contrast 
downregulate ERAD function, thereby helping to establish a persistent infection [320, 
321]. 
? ?
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II. Results: Folding of anthrax toxin receptors  
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Abstract
ANTXR 1 and 2, also known as TEM8 and CMG2, are two type I membrane proteins, which
have been extensively studied for their role as anthrax toxin receptors, but with a still elusive
physiological function. Here we have analyzed the importance of N-glycosylation on folding,
trafficking and ligand binding of these closely related proteins. We find that TEM8 has a
stringent dependence on N-glycosylation. The presence of at least one glycan on each of
its two extracellular domains, the vWA and Ig-like domains, is indeed necessary for efficient
trafficking to the cell surface. In the absence of any N-linked glycans, TEM8 fails to fold cor-
rectly and is recognized by the ER quality control machinery. Expression of N-glycosylation
mutants reveals that CMG2 is less vulnerable to sugar loss. The absence of N-linked gly-
cans in one of the extracellular domains indeed has little impact on folding, trafficking or re-
ceptor function of the wild type protein expressed in tissue culture cells. N-glycans do,
however, seem required in primary fibroblasts from human patients. Here, the presence of
N-linked sugars increases the tolerance to mutations in cmg2 causing the rare genetic dis-
ease Hyaline Fibromatosis Syndrome. It thus appears that CMG2 glycosylation provides a
buffer towards genetic variation by promoting folding of the protein in the ER lumen.
Introduction
N-Glycosylation is one of the most prevalent protein modifications and is largely conserved be-
tween eukaryotes and prokaryotes [1]. Based on bio-informatics analyses, it has been estimated
that more than 50% of all eukaryotic proteins are glycosylated [2] underlining the importance
of these modifications in diverse cellular processes including protein folding, stability, traffick-
ing, endocytosis, cell adhesion and cellular recognition events [3].
N-linked protein glycosylation can be viewed as a two-step process with a first step in the
endoplasmic reticulum (ER) and the second in the Golgi. In the ER, a core oligosaccharide con-
sisting of Glc3Man9GlcNac2 (Glc: glucose, Man: mannose, GlcNAc: N-acetylglucosamine) is at-
tached to asparagine residues within the N-X-S/T consensus sequence and undergoes initial
trimming. When the protein is transported to the Golgi, the oligosaccharide undergoes further
modifications, in particular the addition of complex sugars [4, 5].
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N-glycosylation plays an important role in protein folding in the ER. The core oligosaccha-
ride is attached to the polypeptide chain as it is translocated into the ER lumen across the trans-
locon pore. The two outer glucoses are immediately removed by glucosidases I and II. This
enables association of the nascent polypeptide chain with calnexin or calreticulin, chaperones
involved in ER folding and quality control [6, 7]. These two ER-resident lectins specifically
bind monoglucosylated oligomannose glycans [8]. If folding and, when relevant, oligomeriza-
tion are successful, the newly synthesized protein exits the ER via COPII coated vesicles and is
subsequently routed to its final destination [9].
If folding is aberrantly delayed or unsuccessful, the protein can be targeted to ER-associated
degradation (ERAD) [10]. Prolonged presence in the ER leads to extensive mannose trimming
of the oligosaccharide, which acts as a targeting signal for ERAD [11–13]. Exposed mannoses
are recognized by the ERAD lectins OS-9 and XTP3-B [14–16]. Since degradation is protea-
some mediated, ERAD substrates must be retrotranslocated to the cytoplasm through a ubiqui-
tination-mediated process [17]. Once in the cytosol, the remaining glycans are removed by a
glycanase, before the protein is handed over to the proteasome for degradation [18, 19]. Thus
N-linked sugars play crucial roles first in promoting protein folding via glucose residues and
then targeting the protein to degradation via the mannose residues.
We here investigated the importance of N-glycosylation in the trafficking and function of
two surface receptors probably involved in the homeostasis of the extracellular matrix, namely
TEM8 (tumor endothelial marker 8) and CMG2 (capillary morphogenesis gene 2). TEM8 and
CMG2 are two highly homologous type I membrane proteins, composed of an extracellular
vonWillebrandt A domain (60% identity between the two proteins), an Ig-like domain, a
transmembrane domain and a cytosolic tail that differs in size between the two proteins but is
initiated by a 68% identical domain (S1 Fig.).
TEM8 was discovered as an upregulated gene in human tumor endothelium [20]. It was
subsequently found to serve as a receptor for anthrax toxin, hence the name anthrax toxin re-
ceptor 1 (ANTXR1) [21]. Recent studies describe TEM8 as a cancer [22–24] and cancer stem
cell [25] marker due to its upregulation in tumor, but not physiological, vasculature. Consis-
tently, interfering with TEM8 leads to a decrease in tumor angiogenesis [26–28]. Mutations in
TEM8 can lead to GAPO syndrome, a rare, complex and severe autosomal-recessive disorder
[29, 30].
CMG2 was found as the second most upregulated gene in a 3D culture of endothelial cells
[31]. Its vWA domain was found to bind in vitro to the ECM proteins laminin and collagen
type IV [31]. CMG2 knockout mice display an accumulation of ECM in different organs [32,
33], indicating a role for CMG2 in the homeostasis of ECM. This notion is strengthened by the
pathology of patients afflicted with Hyaline Fibromatosis Syndrome, a disease caused by muta-
tions in cmg2. Patients suffer from the accumulation of a hyaline material in skin and other or-
gans which can be life threatening or highly debilitating [34]. Most reported mutations in the
vWA and the Ig-like domain of CMG2 lead to misfolding of the protein, provoking its reten-
tion in the ER and its degradation by ERAD, resulting in loss of protein function [35]. The
drastic effect of these point mutations suggests a sensitive folding landscape for CMG2.
Both TEM8 and CMG2 contain potential N-glycosylation sites: N166 and N184 in the vWA
and N262 in the Ig-like domain of TEM8, and N250 and N260 in the Ig-like domain of CMG2.
In this study, we show that glycosylation can occur at all potential sites and that glycosylation
is necessary for TEM8 to fold, exit the ER and reach the plasma membrane. We found that
CMG2 is less dependent on glycosylation for folding and thus its N-glycosylation-independent
exit from the ER depends on the folding capacity/ER quality control stringency of the cell. Im-
portantly, the dependence on glycosylation becomes apparent when genetic mutations such as
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those found in Hyaline Fibromatosis Syndrome patients, decrease folding efficiency of the
extracellular domains.
Materials and Methods
Cells and reagents
HeLa cells were grown in Modified Eagle’s medium (MEM) (Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal calf serum, 2 mM L-glutamine, non-essential amino acids, penicillin
and streptomycin. RpeI cells, patient fibroblasts and Flp-In T-REx 293 CMG2 cells (Invitrogen,
Carlsbad, CA) were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum and 2 mM penicillin and streptomycin. For induction of CMG2, Flp-
In T-REx 293 CMG2 cells were treated for 24h with 0.1 μg/ml doxycycline.
The human CMG2 (isoform 4, Uniprot P58335–4) gene, with a V5 epitope at the C-
terminus was cloned in the pcDNA3.1/V5-HIS-TOPO expression vector (Invitrogen, Carlsbad,
CA) and was provided by J. Martignetti (Mount Sinai School of Medicine, New York, NY;
Dowling et al., 2003). For stable cell lines, CMG2 was cloned into the pcDNA5/FRT/TO vector
(Invitrogen, Carlsbad, CA) and transfected cells were selected according to the manufacturer’s
protocol. The human TEM8 (isoform 1, Uniprot Q9H6X2–1) gene with an HA epitope was
cloned in the pIREShyg2 vector (Liu and Leppla, 2003). Mutations were generated using the
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA). All plasmids were
transfected into cells using Fugene according to the manufacturer’s protocol (Promega,
Madison, WI).
Anthrax toxin was purified as described before [36]. Polyclonal goat antibody (#771B)
against Protective Antigen (PA) was from List Biological Laboratories (Campbell, CA) and
used at 1/2000 dilution, monoclonal mouse V5 antibody (#R960–25) was from Invitrogen
(Carlsbad, CA) and used at 1/2000 dilution; monoclonal rat HA-HRP antibody (#12 013 819
001) was from Roche (Basel, Switzerland) and used at 1/2000 dilution; monoclonal mouse Ubi-
quitin antibody (#sc-8017) from Santa Cruz Biotechnology Inc. (Santa Cruz, CA) and used at
1/500 dilution; polyclonal rabbit calnexin antibody was produced by Eurogentec for our lab
[37] and used at 1/2000 dilution; polyclonal rabbit BiP antibody (#ab21685) from Abcam
(Cambridge, UK) used at 1/1000 dilution; polyclonal rabbit antibody against TEM8 was gener-
ated in our lab and used at 1/2000 and polyclonal goat CMG2 antibody (#AF2940) was from
R&D Systems (Minneapolis, MN) and used at 1/2000 dilution.
HRP-conjugated secondary antibodies were from Pierce Chemical Co. (Rockford, IL) and
Alexa-conjugated secondary antibodies fromMolecular Probes (Invitrogen, Carlsbad, CA).
Streptavidin-agarose conjugated beads were from Sigma-Aldrich (St. Louis, MO), protein G
beads were from GE Healthcare (Uppsala, Sweden) and HA-beads from Roche (Basel,
Switzerland);
Treatments with N-glycosidase and Endoglycosidase H (New England Biolabs, Ipswich,
MA) were performed as previously described [38].
Immunofluorescence
Transiently transfected HeLa cells were fixed with 4% paraformaldehyde and permeabilized
with 0.1% Triton X100, and stained with antibodies against the V5 or HA tag and the ER mark-
er BiP followed by an appropriate secondary antibody. Images were acquired using a Plan-
Apochromat 63x/1.4 oil objective on a Zeiss LSM 710 (Carl Zeiss Microimaging, Thornwood,
NY), equipped with an AxiocamMRm camera using the Zen 2009 acquisition software. FIJI
and Adobe Illustrator software were used to prepare the figures.
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Surface biotinylation and immunoprecipitation
For immunoprecipitation, confluent cells were washed three times with PBS. Cells were lysed
by incubation for 30 min at 4°C with 0.5% NP-40, 500 mM Tris-HCl, pH 7.4, 20 mM EDTA,
10 mMNaF, 30 mM sodium pyrophosphate decahydrate, 2 mM benzamidine, 1 mM PMSF, 1
mMNEM and a cocktail of protease inhibitors (Roche, Basel, Switzerland). Cells lysates were
incubated overnight at 4°C with anti-V5 antibody and protein G sepharose beads for CMG2,
or HA-beads for TEM8. For the ubiquitination assay, cells were treated for 4h with 10 μM
MG132 or 0.1 μM Bafilomycin A1 (Sigma) before cell lysis.
For surface biotinylation, confluent cells were incubated with 0.2 mg/ml NHS-SS-biotin
(Pierce) in PBS for 30 min at 4°C and washed 3x 10 min with sterile PBS containing 100 mM
NH4Cl. Cells were lysed and the lysate was immunoprecipitated with streptavidin-coated aga-
rose beads. After SDS-PAGE and Western blotting against the V5 or HA antibody, biotinylated
CMG2 or TEM8 proteins and expression level were quantified with Image Quant TL 2005 /
Typhoon software (GE Healthcare) or BioID software (Fusion). Biotinylated proteins values
were normalized to expression level values. Expression of mutants at the cell surface was nor-
malized to that of the WT protein. To assess surface expression of non-glycosylated endoge-
nous protein, cells were treated with 5 μg/ml tunicamycin (Sigma) for 16h and then labeled as
described above.
For in vivo anthrax protective antigen (PA) binding, transiently transfected HeLa cells were
incubated for 1h at 4°C with 500 ng/ml PA83 in internalization medium (IM medium), (Glas-
gow minimal essential medium, Invitrogen, 10mMHEPES, pH 7.4). Cells were washed twice
with warm IMmedium to remove excess toxin and incubated for 10 min at 37°C to induce
cleavage and heptamerization. Cells were then lysed and immunoprecipitated against TEM8-
HA or CMG2-V5. For in vitro PA binding, transiently transfected HeLa cells were lysed and
the lysate was incubated for 1h at 4°C with 1μg/ml PA83. Lysates were immunoprecipitated
against TEM8-HA or CMG2-V5.
Graphics
Molecular graphics and analyses were performed with the UCSF Chimera package [39]. For
TEM8, the graphic is based on structure 3N2N from the Protein Data Bank (http://www.rcsb.
org/pdb/). For CMG2, the graphic is based on structure 1TZN from PDB and on modeling
from [40].
Ethical Statement
Primary Human fibroblasts from a control and a Hyaline Fibromatosis syndrome patient were
obtained with patient consent, research using these cells was approved by the “Commission
Cantonale d’éthique de la recherche sur l’être humain” and are registered under the approval
No A070055 of the Swiss Federal Office of the Environment. Patients provided written consent
that patient derived cells could be used in any studied aimed at a better understanding of Hya-
line Fibromatosis syndrome and the gene involved. The patient signed a standard consent
form approved by the ethics committee.
Results
TEM8 and CMG2 can undergo N-glycosylation on all predicted sites
TEM8 and CMG2 have been shown to be glycosylated, yet the location and number of sites
have not been determined [38]. They respectively contain 3 and 2 predicted N-glycosylation
sites, of which only one is conserved: N262 in TEM8 corresponding to N260 in CMG2 within
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the Ig-like domain (Fig. 1A). To test whether these sites can be modified, we generated single,
double and triple asparagine mutants. Expression of the mutants was analyzed by transient
transfection of HeLa cells (Fig. 1BC). For both TEM8 and CMG2, mutation of a single aspara-
gine residue, at whatever position, was sufficient to induce a change in electrophoretic mobility.
The most dramatic change was observed when mutating the conserved site in the Ig-like do-
main (N262/N260, Fig. 1BC). Mobility increased as more asparagines were mutated. Also,
TEM8 and CMG2, which migrate as smears when WT, migrated as a well-defined single band
as glycosylation sites were mutated (Fig. 1BC). All together this analysis indicates that all sites
can be modified in WT TEM8 and CMG2.
To confirm that all predicted sites can indeed be glycosylated, Total Cell Extracts (TCE) of
cells expressing the mutants were treated with N-Glycosidase F (NGaseF), an enzyme that re-
moves all glycan side chains of a protein, regardless of their modification or localization [41].
For both TEM8 and CMG2, NGaseF-treatment led to a change in electrophoretic mobility of
WT and all mutants, with the exception of the mutants with all potential sites mutated
(Fig. 1DE), indicating that all sites can be modified in vivo. Note that all sites might not be
modified simultaneously, and thus cells might express differentially glycosylated species.
Fig 1. CMG2 and TEM8 can undergo N-glycosylation on all predicted sites. A)Graphics depicting glycosylation sites on TEM8 and CMG2. Sites in red
are unique to the respective proteins, N260 in CMG2 (yellow) corresponds to N262 in TEM8.B) Expression of TEM8 glycosylation mutants in HeLa cells.
Cells were transfected for 48h with the respective cDNAs. Expression was analyzed by SDS-PAGE andWestern Blotting.C) Expression of all CMG2
glycosylation mutants in HeLa cells. Cells were transfected for 48h with the respective cDNAs. Expression was analyzed by SDS-PAGE andWestern
Blotting. D) Endoglycosidase F (NGaseF) treatment on TEM8 glycosylation mutants. 40 μg of cell extracts were treated or not with NGaseF and analyzed by
SDS-PAGE andWestern Blotting. E) Endoglycosidase F (NGaseF) treatment on CMG2 glycosylation mutants. 40 μg of cell extracts were treated or not with
NGaseF and analyzed by SDS-PAGE andWestern Blotting.
doi:10.1371/journal.pone.0119864.g001
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The number of glycan sidechains and their localization determine
trafficking efficiency of the protein
The first hurdle for any protein is to fold. Because glycosylation has been shown to promote
folding of certain proteins such as the multi-pass membrane protein cystic fibrosis transmem-
brane conductance regulator CFTR [42] or human immunodeficiency virus-1 (HIV-1) protein
gp120 [43], we investigated whether mutating glycosylation sites in CMG2 and TEM8 affects
their folding. As a readout, we utilized the modification of N-linked sugars by Golgi enzymes
since proper folding is a prerequisite for ER exit and trafficking to the Golgi apparatus. Modifi-
cation of N-linked sugars by Golgi enzymes renders them insensitive to the enzyme Endoglyco-
sidase H (EndoH). Transiently expressed WT TEM8 or CMG2 migrate as a smear,
corresponding to the Golgi modified form, and a lower molecular weight band, corresponding
to the immature ER form, which is EndoH sensitive [35, 38]. All single CMG2 and TEM8 gly-
cosylation mutants migrated as an EndoH insensitive smear and an EndoH sensitive band, in-
dicating that a fraction of all mutants is able to fold correctly, exit the ER and reach the Golgi
(Fig. 2A). Fully glycosylation deficient mutants cannot be analyzed using this assay.
Following sugar modification in the Golgi, CMG2 and TEM8 are transported to the plasma
membrane where they exert anthrax toxin receptor and presumably physiological functions.
To assess whether glycosylation influences surface targeting, we performed a surface biotinyla-
tion assay. This assay allows the affinity isolation of the surface population and comparison to
the overall expression levels. Mutation of either of the two vWA domain glycosylation sites in
TEM8, N166 and N184, did not affect surface expression when compared to WT, but simulta-
neous mutation of both led to a 50% decrease in surface expression (Fig. 2BC). A similar drop
in surface expression was observed when mutating N262 in the Ig-like domain (Fig. 2BC). A
pronounced drop in surface expression was observed when all three sites where modified
(Fig. 2BC). Thus TEM8 requires two N-linked glycans for efficient trafficking to the cell sur-
face, of which one site must be N262.
For CMG2, loss of either of the two glycosylation sites within the Ig-like domain lead to a
30% drop in plasma membrane targeting (Fig. 2DE). Surface targeting was also impaired when
both sites were absent (Fig. 2DE), yet at least 50% was still properly addressed to the
plasma membrane.
Thus plasma membrane targeting of both TEM8 and CMG2 is enhanced by the presence of
two N-linked sugars, one of which must reside in the Ig-like domain.
TEM8 glycosylation promotes ER exit
The surface biotinylation analysis indicates that fully glycosylation-deficient TEM8 and CMG2
do not or only partially reach the plasma membrane. We analyzed their localization by immu-
nofluorescence microscopy. As expected, the WT form of TEM8 and CMG2 could be detected
at the plasma membrane as well as intracellular structures (Fig. 3AB and S2 Fig.). Plasma mem-
brane staining was also observed for CMG2 2NA (Fig. 3B and S2 Fig.). Note that immunofluo-
rescence does not allow a quantitative analysis of surface expression as does surface
biotinylation (Fig. 2). In contrast, the triple 3NA TEM8 mutant was absent from the plasma
membrane and showed clear ER staining, co-localizing with the ER chaperone BiP (Fig. 3A).
Non-glycosylated TEM8 is an ER quality control and ERAD substrate
The above observations indicate that glycosylation promotes ER exit, raising the possibility
that in the full absence of glycosylation, folding in the ER is impaired, leading to recognition of
the protein by the ER quality control and possible targeting to ERAD. To address this issue, we
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monitored the ubiquitination status of TEM8 and CMG2, since this post-translation modifica-
tion is required for targeting the protein to the proteasome. Since ubiquitination might lead to
rapid degradation, rendering the species undetectable, we treated cells with the proteasome in-
hibitor MG132. We also monitored the effect of Bafilomycin A1, which inhibits acidification of
the endosome, thereby preventing lysosomal protein degradation, since this is the second
major protein degradation route in the cell. Inhibitors were used only for a few hours to mini-
mize the potential secondary effects on protein translation for example. For both WT and the
N262A mutant of TEM8, a limited smear of ubiquitination was observed, which was enhanced
Fig 2. Number and localization of glycan sidechains determine trafficking efficiency of TEM8 and CMG2. A) Endoglycosidase H (EndoH) treatment on
TEM8 and CMG2 single mutants. HeLa cells were transfected for 48h with the respective cDNAs. 40 μg of cell extracts were treated or not with EndoH as
described before. Samples were analyzed by SDS-PAGE andWestern Blotting. B)Quantification of surface biotinylation experiments to determine amount
of TEM8 at the cell surface. All mutants were corrected for their expression levels and then normalized to WT, which was set at 100%. Errors represent
standard deviation. Statistics were calculated using an unpaired t-test. n 3. * p0.05, ** p0.01, *** p0.001C) Representative Western Blots of surface
biotinylation. HeLa cells were transfected 48h with the respective cDNAs. Proteins at the cell surface were labeled with biotin, immunoprecipitated with
streptavidin beads and blotted against TEM8-HA. D)Quantification of surface biotinylation experiments to determine amount of CMG2 at the cell surface. All
mutants were corrected for their expression levels and then normalized to WT, which was set at 100%. Errors represent standard deviation. Statistics were
calculated using an unpaired t-test. n 3. * p0.05, ** p0.01, *** p0.001 E) Representative Western Blots of surface biotinylation. HeLa cells were
transfected 48h with the respective cDNAs. Proteins at the cell surface were labeled with biotin, immunoprecipitated with streptavidin beads and blotted
against CMG2-V5.
doi:10.1371/journal.pone.0119864.g002
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by Bafilomycin A1 treatment, consistent with an ubiquitination-mediated targeting of TEM8
from the plasma membrane to lysosomes [38]. MG132 treatment led, as expected, to the ap-
pearance of a long smear, a hallmark of polyubiquitination, the targeting signal for the protea-
some (Fig. 4A). These observations are consistent with the fact that upon transient expression
of WT TEM8, the majority is targeted to the cell surface, from where degradation occurs in ly-
sosomes, while a smaller a fraction remains in the ER and is degraded by the proteasome (Figs.
1 and 2). When a similar analysis was performed for the 3NA TEM8 mutant, no effect was
Fig 3. Localization of TEM8 and CMG2 glycosylation mutants. A) Immunofluorescence of transiently
transfected HeLa cells. Cells were transfected for 48h with the respective cDNAs. Cells were fixed,
permeabilized and stained for TEM8-HA, endogenous BiP and Hoechst. Scalebars represent 10 μm.B)
Immunofluorescence of transiently transfected HeLa cells. Cells were transfected for 48h with the respective
cDNAs. Cells were fixed, permeabilized and stained for CMG2-V5, endogenous BiP and Hoechst. Scalebars
represent 10 μm.
doi:10.1371/journal.pone.0119864.g003
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observed upon Bafilomycin A1 treatment, consistent with the absence of TEM8 3NA at the
plasma membrane. However a long smear, revealing polyubiquitination, was observed under
control conditions and strongly enhanced upon MG132 treatment (Fig. 4A, lane 8). All togeth-
er this analysis indicates that the 3NA TEM8 mutant is retained in the ER and targeted to the
ERAD pathway. Note that while the majority of WT TEM8 folds and exists the ER, targeting to
ERAD is also observed indicating that the efficiency of TEM8 folding is not 100%.
For CMG2, the ubiquitination pattern of WT and mutants was qualitatively similar, in all
cases sensitive to both drugs, with a higher molecular weight smear upon MG132 treatment
and a lower molecular weight smear upon neutralization of lysosomes (Fig. 4B). This behavior
is consistent with our finding that a significant percentage (50%, Fig. 2D) of even the 2NA mu-
tant reaches the plasma membrane.
The above experiments indicate that non-glycosylated TEM8 is retained in the ER and po-
tentially an ERAD substrate, while CMG2, under these experimental conditions, is less depen-
dent on glycosylation for its proper expression.
The above experiments were performed in HeLa or HEK cells transiently expressing TEM8
or CMG2WT and glycosylation mutants and allowed us to reveal a differential sensitivity to
glycosylation. Different cell types however have different capacities of protein folding and ER
Fig 4. Non-glycosylated TEM8 is an ER quality control and ERAD substrate. A) HeLa cells were transfected for 48h with the respective cDNAs. Cells
were treated or not with MG132, an inhibitor of the proteasome or Bafilomycin A1, a drug preventing endosomal acidification and thus lysosomal degradation.
Immunoprecipitates against TEM8-HA were analyzed by SDS-PAGE andWestern Blotting against Ubiquitin and TEM8-HA.B)HEK cells stably expressing
CMG2 under the control of a tetracycline inducible promotor were induced for 24h with 0.1μg/ml doxycycline. Cells were treated or not with MG132 or
Bafilomycin A1. Immunoprecipitates against CMG2-V5 were analyzed by SDS-PAGE andWestern Blotting against Ubiquitin and CMG2-V5. C)HeLa
cells were treated or not with tunicamycin, an antibiotic blocking the co-translational transfer of glycan sidechains in the ER by blocking the
oligosaccharyltransferase (OST) for 16h. Surface proteins were labeled with biotin and immunoprecipitates against streptavidin were analysed for TEM8 or
Calnexin as a negative control.D)RpeI cells were treated or not with tunicamycin for 16h. Surface proteins were labeled with biotin and immunoprecipitates
against streptavidin were analysed for CMG2 or Calnexin as a negative control.
doi:10.1371/journal.pone.0119864.g004
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quality control [44]. Also overexpression might saturate the ER capacity to promote folding of
the overexpressed protein of interest. We therefore next monitored endogenously expressed
proteins, TEM8 in HeLa cells (which do not express CMG2) and CMG2 in Rpe1 cells [45, 46].
N-glycosylation was prevented by treating cells for 16h with tunicamycin, a drug inhibiting the
transfer of the core oligosaccharide to the nascent polypeptide chain by oligosaccharyltransfer-
ase (OST). Tunicamycin treatment led to a complete loss of TEM8 protein (Fig. 4C). Even after
surface biotinylation and enrichment of surface proteins with streptavidin beads, TEM8 was
undetectable. In contrast, expression of CMG2 was not significantly modified by tunicamycin
(Fig. 4D). The CMG2 band migrated at a lower molecular weight as expected from the absence
of glycosylation. Importantly, non-glycosylated CMG2 was transported to the cell surface as re-
vealed by surface biotinylation. Since tunicamycin disrupts N-glycosylation of all proteins in
the cell, the loss of TEM8 could potentially be due to gross secondary effects. This is however
unlikely given the fact that these results are fully consistent with the surface biotinylation ex-
periments performed on the glycosylation mutants and the lack of effect of tunicamycin on
CMG2, which is highly homologous to TEM8. These experiments confirm that endogenous
TEM8 is highly dependent on glycosylation for its expression, while in Rpe1 cells, endogenous
CMG2 does not significantly rely on glycosylation for its plasma membrane targeting.
Loss of glycosylation affects binding of Anthrax toxin to TEM8 but not to
CMG2
Since glycosylation is not required for targeting of CMG2 to the plasma membrane, we next in-
vestigated whether it is required for its ability to bind its ligand. Parallel experiments were per-
formed for TEM8. We used protective antigen (PA), the receptor binding subunit of the anthrax
toxin, as a surrogate ligand. As a negative control, we used the D50Amutants of both receptors,
which harbors a mutation in the ligand-binding domain and therefore cannot bind PA [47, 48].
We monitored binding of full-length PA (PA83) to the receptor, the processing to its 63 kDa
form (PA63) and the conversion of the 63 kDa form into an SDS-resistant oligomeric form
(PA7mer), using SDS-PAGE and Western Blotting. The presence of oligomers indicates that PA
has been transported to endosomes, where the conversion to the membrane inserted SDS-resis-
tant form occurs [49]. Upon addition of PA to cells expressing any of the single TEM8 mutants,
we observed a decrease in PA binding, cleavage, and heptamer formation, as compared to WT.
Only monomers were observed in immunoprecipitates of the N262A mutant (Fig. 5A). This
could be due either due lower binding, impaired oligomerization or enhanced release of the
oligomer from the receptors [50]. The triple, fully glycosylation-deficient TEM8 mutant failed
to bind PA (Fig. 5A), not surprising given its ER localization. Since differences observed in this
assay might, at least partly, be due to a decrease in surface expression of the mutants, we next
monitored PA binding in vitro. In this assay, PA is added to cell lysates, bypassing the localiza-
tion issue [35]. Of the single TEM8 mutants, only N262A showed a severe decrease in binding
when compared to the WT. This was also true for double mutants and PA binding became es-
sentially undetectable for the triple asparagine TEM8 mutant (Fig. 5B). Thus, glycosylation of
TEM8, in particular at position 262, is required for efficient PA binding. Recombinant, bacteri-
al expressed, TEM8 vWA domain is fully competent for PA binding [51], thus glycosylation
per se is not required for ligand binding. Therefore the absence of PA binding to the 3NA mu-
tant is likely due to a defect in folding in the cellular context in the absence of glycosylation,
which would be consistent with the full ER retention of TEM8 3NA. In contrast, for CMG2,
both in vivo and in vitro binding assays showed no significant difference in binding, cleavage,
or heptamer formation between WT and mutant proteins partially or fully deficient in glyco-
sylation (Fig. 5CD).
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Glycosylation acts as a buffer for CMG2 ectodomain mutations
Our study reveals that in Rpe1 cells or upon transfection into HeLa cells, CMG2 is only mildly
sensitive to the loss of N-glycosylation. Our analyses of Hyaline Fibromatosis Syndrome (HFS)
mutations have however revealed that CMG2 is rather sensitive to ectodomain mutations in
terms of folding [35, 40]. Indeed most ectodomain missense mutations were found to lead to
defects in ER folding and targeting to ERAD [35, 40]. We therefore hypothesized that N-
glycosylation of CMG2 might favor folding in the presence of protein destabilizing mutations
and thus serve as a “buffer” for genetic variation. To test this hypothesis, we searched for a HFS
inducing mutation that localizes to the ectodomain of CMG2 but does not affect plasma mem-
brane targeting. This is a rare situation since we have found that most ectodomain mutations
lead to CMG2 degradation by ERAD [35, 40]. We found a homozygous patient carrying the
c.652T>C mutation which leads to p.C218R. Modification of Cys-218 leads to the disruption
of the disulfide bond that links the N and C-termini of the vWA domain (Fig. 6A). We have
previously shown that upon transient overexpression in tissue culture cells, the C218R mutant
has a partial folding defect, leading to a 60% drop in surface expression yet its ability to bind
Fig 5. Loss of glycosylation affects binding of Anthrax toxin to TEM8 but not to CMG2. A and C) HeLa cells were transfected for 48h with the
respective cDNAs. Cells were treated for 1h at 4°C with 500 ng/ml PA83 and shifted to 37°C for 10 min to induce cleavage and heptamerization.
Immunoprecipitates against TEM8-HA/CMG2-V5 were analyzed by SDS-PAGE andWestern Blotting against PA and TEM8-HA/CMG2-V5. Control cells are
non-transfected. D50A is a binding deficient mutant that serves as a negative control. B and D) HeLa cells were transfected for 48h with the respective
cDNAs. Cells were lysed and incubated for 1h at 4°C with 1 μg/ml PA83. Immunoprecipitates against TEM8-HA/CMG2-V5 were analyzed by SDS-PAGE and
Western Blotting against PA and TEM8-HA/CMG2-V5. Control cells are non-transfected. D50A is a binding deficient mutant that serves as a negative control.
doi:10.1371/journal.pone.0119864.g005
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Fig 6. Glycosylation acts as a buffer for CMG2 ectodomain mutations. A)Graphic showing the disulfide
bridge C39-C218 (blue) present in CMG2WT B) Fibroblast cells were treated or not with tunicamycin for 16h
and TCE were analyzed by SDS-PAGE andWestern Blot. Representative Western Blot with control
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PA is not impaired [35, 40]. Instead of transient expression in tissue culture cells, we could ana-
lyze patient cells. As shown in Fig. 6, CMG2 is expressed at the same level in cells from the
C218R expressing patient as in cells from a control patient. Also the migration pattern of
C218R CMG2 was similar to that of WT CMG2, indicating that sugar modifications and in
particular addition of complex sugars in the Golgi had occurred. To investigate the importance
of CMG2 glycosylation in patient-derived fibroblasts, cells were treated with tunicamycin. In
marked contrast to what we observed in the tissue culture cell line Rpe1, expression of WT
CMG2 dropped by 70% upon tunicamycin treatment indicating that in these primary human
fibroblasts, glycosylation was required for efficient expression of WT CMG2. Consistently,
tunicamycin also led to a drastic drop of the C218R CMG2 HFS variant (Fig. 6BC). Interesting-
ly, the comparison of WT to C218R CMG2 expression under conditions of tunicamycin treat-
ment showed that C218R expression was almost three fold lower than that of WT. Thus C218R
is in fact a protein destabilizing mutation, but this is no longer apparent in the presence of gly-
cosylation, a situation in which its expression is similar to that of WT. Thus consistent with
our hypothesis, glycosylation appears to overcome the folding defect generated by the C218R
mutation. As opposed to most other ectodomain mutations, C218R does not lead to a major
loss of protein expression at the cell surface but to a loss of protein function, which we are
currently addressing.
Discussion
TEM8 and CMG2 are two transmembrane surface glycoproteins involved in homeostasis of
the extracellular matrix but can also act as anthrax toxin receptors. Mutations in the tem8 or
cmg2 genes may lead to two severe genetic diseases, GAPO syndrome [29, 30] and Hyaline
Fibromatosis syndrome, respectively [34]. While the genetic origin of GAPO syndrome has
only recently been identified and thus no genotype-phenotype studies have yet been reported,
our studies on the HFS mutations indicate that the disease is due to a loss of protein function,
often as a consequence of the loss of protein expression [40]. Depending on the specific patient
mutations, the defects of CMG2 expression were attributed to premature mRNA degradation
or impaired folding in the ER. This led us to investigate the potential role of N-glycosylation on
the folding and subsequent trafficking of TEM8 and CMG2.
We show that both proteins can undergo N-glycosylation on all of their predicted sites,
three in TEM8 and two in CMG2, of which only one is conserved and localizes to the Ig-like
domain. Transient overexpression experiments in tissue culture cells reveal that optimal ex-
pression is achieved when all sites are available to be modified. The requirement for glycosyla-
tion was however less stringent for CMG2 since a significant fraction of the protein was found
to exit the ER, indicating proper folding, reach the plasma membrane and bind its ligand in the
absence of N-linked sugars. In contrast, fully glycosylation-deficient TEM8 was retained in the
ER and failed to bind anthrax PA toxin, together suggesting that folding was impaired. TEM8
was in fact affected by the loss of any of its glycosylation sites, and losses were to a large
extent additive.
That sugars promote protein folding, trafficking and function has been reported for a varie-
ty of proteins, as reviewed in [3, 52]. Proteins that depend on glycosylation for folding and
other functions are diverse and range from mammalian to viral and bacterial proteins [53, 54].
fibroblasts and patient fibroblasts. Calnexin serves as a loading control. C)Quantification of total protein
levels. CMG2 levels are normalized to WT protein level without tunicamycin treatment, which was set to
100%. Statistics were calculated using an unpaired t-test. Errors represent standard deviation. n 3.
* p0.05
doi:10.1371/journal.pone.0119864.g006
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Depending on where the glycosylation sites are localized in proteins, sugars can have a local or
a global impact on the protein, i.e. by influencing the secondary structure in the vicinity of the
modified residue [55, 56]. The presence of sugars affects the hydrophilicity of the protein but
also provides the opportunity to interact with lectin chaperones such as calnexin, further in-
creasing the positive effect on folding. The present work leads to the unexpected finding that
two proteins that are very closely related and show a high degree of sequence identity/similarity
(S1 Fig.), differ significantly in their dependence towards glycosylation.
The tolerance of CMG2 toward the lack of glycosylation was however only apparent in cer-
tain cell types (HeLa and Rpe1 tested here). In primary human fibroblasts however, glycosyla-
tion of CMG2 appeared essential for proper expression, since tunicamycin led to a 70% drop in
expression. This differential behavior likely reflects the difference in expression of the folding
and quality control arsenal expressed by these cells. It has indeed been reported that the expres-
sion of chaperone and folding enzymes greatly differs between cells and tissues [44]. It could
thus be that primary cells have a poorer folding capacity, a more stringent ER quality control
and/or a more potent ERAD pathway, and that under these conditions optimal folding of
CMG2 can only be achieved in the presence of N-linked glycans.
Moreover, glycosylation appears to provide a buffer towards genetic variation. Glycosylation
would render CMG2 more tolerant to mutations that fail to fold without the assistance of lectin
chaperones. Consistent with this hypothesis, we found that in the absence of glycosylation,
C218R CMG2 was expressed at 30% of WT, whereas under normal glycosylation conditions,
expression was similar to WT.
That chaperones can act as buffers for genetic variations has previously been shown. This
might not only help proteins that have acquired a mutation to fold, but could also be a driver
for genetic variation and evolution [57–59]. Our results now suggest a variation on this theme:
by being modified with glycan side chains, a protein is more prone to interact longer or more
often with lectin chaperones. This in turn would help the protein to fold correctly even if it har-
bors a destabilizing mutation. The glycosylated form of the protein would be more tolerant to
mutations while not affecting or even promoting function. One could even envision that some
mutants have a beneficial increased occupancy of the glycosylation sites. It was indeed observed
that excessive N-glycosylation of Aquaporin 2 mutants increased their stability and promoted
folding, thereby partly preventing their degradation [60]. The importance of N-glycosylation
in protecting TEM8 and CMG2 will be further tested, as mutations in the encoding genes iden-
tified in GAPO and HSF patients will be reported.
Supporting Information
S1 Fig. Alignment of human TEM8 and CMG2. Sequence alignment using Jalview [61] for
human TEM8 (ANTR1) isoform 1 and CMG2 (ANTR2) isoform 4. Indicated are the domains
of the proteins as well as the glycosylation sites (asterisks).
(TIF)
S2 Fig. Immunofluorescence of TEM8WT and CMG2WT and N260A. Images shown in
Fig. 3 of TEM8WT, CMG2WT and N260A with an additional zoomed image.
(TIF)
S3 Fig. Original blots of Figs. 1, 2 and 4. Uncropped blots shown in Figs. 1,2 and 4. Indicated
is the area that was used for the figures.
(TIF)
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S4 Fig. Original blots of Figs. 5 and 6. Uncropped blots shown in Figs. 5 and 6. Indicated is
the area that was used for the figures.
(TIF)
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?
S1 Fig .  Alignment  o f  human TEM8 and CMG2 Sequence alignment using Jalview for human 
TEM8 (ANTR1) isoform 1 and CMG2 (ANTR2) isoform 4.  Indicated are the domains of the proteins as 
well as the glycosylation sites (asterisks).  
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Friebe et al., Fig. S2 
?
?
S2 Fig .  Immunof luore s c ence  o f  TEM8 WT and CMG2 WT and N260A Images shown in 
Figure 3 of TEM8 WT, CMG2 WT and N260A with an additional zoomed image. 
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Friebe et al., Fig. S3 
?
?
S3 Fig .  Orig ina l  b lo t s  o f  Figures  1 ,  2  and 4 Uncropped blots shown in Figure 1,2 and 4. Indicated is 
the area that was used for the figures  
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Friebe et al., Fig. S4 
?
?
S4 Fig .  Orig ina l  b lo t s  o f  Figures  5 and 6 Uncropped blots shown in Figure 5 and 6. Indicated is the 
area that was used for the figures 
?  
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II. Results: Endocytosis of anthrax toxin receptors 
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Abstract 
 
CMG2 and TEM8 are two vertebrate-specific membrane proteins, identified as receptors 
of the anthrax toxin, a major virulence factor of the pathogenic bacterium Bacillus 
anthracis. These proteins are essential for the toxin to access target cells. Their 
physiological roles have however remained largely elusive, but their importance is 
highlighted by the fact that loss of function mutations in either protein leads to rare 
genetic diseases: Hyaline Fibromatosis Syndrome for CMG2, and GAPO syndrome for 
TEM8.  
To better understand both the physiological and pathological roles of CMG2, we have 
searched for partner proteins using yeast-two hybrid screening. We identified and 
validated 4 new partners. We found that the E3 ligase Cbl and the serine-threonine 
kinase MARK2 are involved in regulated endocytosis of the anthrax toxin via both the 
CMG2 and TEM8 mediated pathways. Interestingly we found two proteins specifically 
affecting CMG2-mediated toxin endocytosis, the E3 ligase RNF41 and the 
deubiquitinating enzyme USP8.  
We also assessed physiological endocytosis of the receptors and found that both CMG2 
and TEM8 internalize even in the absence of their pathological ligand. This endocytosis 
is triggered by binding of a physiological ligand to CMG2 and subsequent clustering of 
the receptor. TEM8 undergoes constitutive endocytosis, which is enhanced upon ligand 
binding. Our work provides important insights into both pathological as well as 
physiological endocytosis of the two anthrax toxin receptors.   
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Introduction 
 
Anthrax is an infectious disease, which is largely caused by the exotoxins of B. anthracis. 
Anthrax toxin is a tripartite toxin and consists of protective antigen (PA), the receptor 
binding subunit, as well as edema factor (EF) and lethal factor (LF), the two enzymatic 
subunits of the toxin. PA will bind to one of the two anthrax toxin receptors, TEM8 or 
CMG2 on the cell surface [1, 2]. The full length form is 83 kDa (PA83), which will be 
cleaved by furin to the smaller 63 kDa form (PA63) [3]. The receptor-toxin complexes 
will then multimerize either into heptamers (PA7mer) or octamers [4, 5] and partition into 
specific microdomains of the plasma membrane [6]. The enzymatic subunits EF and LF 
can then bind to the multimer and the whole complex is internalized via clathrin-
mediated endocytosis [7]. This process is regulated by phosphorylation and 
ubiquitination [8, 9]. Once in the endocytic pathway and therefore exposed to a lower 
pH, the PA multimer inserts into the membrane and allows for translocation of the 
enzymatic subunits across the membrane into the lumen of intraluminal vesicles (ILV) 
[10]. Both enzymatic subunits need to eventually reach the cytosol to function but can 
also be kept in ILVs for long-term storage and also release by exosomes as an efficient 
long-term and long-distance transmitter mechanism [11]. 
The anthrax toxin receptor responsible for lethality in mice is CMG2 [12], which was 
discovered as anthrax toxin receptor 2 (ANTXR2) in 2003 [1]. It is a type I 
transmembrane protein, with an extracellular von Willebrand A and an Ig-like domain 
[13]. The vWA domain is involved in binding PA and presumably the physiological 
ligand as well, as mutations in the ligand-binding site lead to the genetic disease Hyaline 
Fibromatosis Syndrome. The Ig-like domain, with so far uncharacterized function, 
contains two glycosylation sites. Glycosylation at these sites promotes folding of CMG2 
in the ER, providing a buffering capacity for this mutation-prone protein [14]. After the 
single transmembrane span, CMG2 has a 148 amino acid long tail, which is predicted to 
be intrinsically unstructured and contains a conserved cytoskeleton-binding domain [13].   
CMG2 was initially identified as the second most upregulated gene in in vitro capillary 
morphogenesis, hence the name Capillary Morphogenesis Gene 2 [15]. Mutations in cmg2 
were then found to cause the rare but severe genetic disease Hyaline Fibromatosis 
Syndrome (HFS) [16, 17]. The most prevalent symptom of this disease is the 
accumulation of hyaline material in the skin and organs of the patients [18], creating 
nodules mostly at sites of mechanic stress [19]. CMG2 knockout mice display a marked 
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fibrosis of the uterus, with an accumulation of fibronectin and collagens I and VI [20, 
21]. In vitro studies indicate that CMG2 binds proteins of the extracellular matrix such as 
laminin and collagen IV [15]. Thus, although the exact role remains elusive, CMG2 
appears to be involved in the homeostasis of the extracellular matrix.  
The only protein in the genome that shows high homology to CMG2 is TEM8 [13], also 
called anthrax toxin receptor 1 (ANTXR1) [2], since it was the first protein identified as 
an anthrax toxin receptor. Mutations in tem8 lead to another severe human genetic 
disease, GAPO syndrome [22]. While the apparent symptoms of Hyaline Fibromatosis 
and GAPO syndromes are very different, they share the accumulation of extracellular 
matrix proteins in different tissues. How the loss of CMG2 and TEM8 function leads to 
the accumulation of extracellular matrix is completely unclear. Given the opportunistic 
nature of bacterial pathogens, it is tempting to speculate that PA has hijacked the ability 
of CMG2 and TEM8 to bind and internalize an endogenous ligand.  
Using a FACS-based assay we have analyzed endocytosis of CMG2 and TEM8 in the 
absence and presence of endogenous ligand and upon binding of the anthrax protective 
antigen. By studying the physiological entry of the two anthrax toxin receptors in the 
absence of their pathological ligand anthrax, we could show that both receptors 
internalize constantly from the cell surface. This internalization is dependent on ligand-
binding and multimerization of the receptor.  
Yeast-Two-Hybrid screens led us to investigate the role of four proteins in CMG2 and 
TEM8-mediated anthrax toxin entry: RNF41, an E3 ubiquitin ligase, MARK2, a 
serine/threonine kinase, Cbl, the E3 ligase for TEM8, and USP8, a deubiquitinating 
enzyme. We found that MARK2, Cbl and USP8 regulate either the surface expression or 
endocytosis of both receptors, while RNF41 specifically affects CMG2 uptake. 
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Material and Methods 
 
Cells and reagents 
RpeI cells, RpeI shTEM8 or shCMG2 and patient fibroblasts were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum and 2 mM 
penicillin and streptomycin.  
 
The human CMG2 (isoform 4, Uniprot P58335-4) gene, tagged with a V5 epitope at the 
C-terminus, was cloned in the pcDNA3.1/V5-HIS-TOPO expression vector 
(Invitrogen, Carlsbad, CA) and provided by J. Martignetti (Mount Sinai School of 
Medicine, New York, NY; [16]). The ΔCBD mutant, missing residues 368-418, tagged 
with a V5 epitope at the C-terminus was cloned in the pIRES vector (Clontech, Japan). 
The human RNF41 (Uniprot Q9H4P4), both full length and the dominant-negative 
carboxy terminus, tagged with a Flag epitope at the C-terminus were cloned in the 
pcDNA3.1 expression vector (Invitrogen, Carlsbad, CA) and provided by K. Carraway 
III (UC Davis, Sacramento, CA; [23]).  
All plasmids were transfected into cells using Fugene (Roche, Basel, Switzerland).  
 
For knockdown experiments, cells were treated with 100 nmol siRNA/6cm dish for 72 h 
prior to experiments. siRNA against RNF41 (SI04267655), MARK2 (SI00288288) and 
USP8 (SI00073017) was from Qiagen (Venlo, The Netherlands). siRNA against c-Cbl 
(sc-29242) was from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). As a control, non-
targeting siRNA (ATTGAACAAACGAAACAAGGA) was used. Transfection was done 
with Interferrin from Polyplus Transfections (Illkirch, France) according to the 
manufacturer’s protocol. 
 
Anthrax toxin was purified as described [24] or produced in our lab. For toxin 
experiments, cells were treated for 1 h at 4°C with 500 ng/ml PA83 in internalization 
medium (IM medium), (Glasgow minimal essential medium, Invitrogen, 10mM HEPES, 
pH 7.4). Cells were washed twice with warm IM medium to remove excess toxin and 
incubated for different timepoints at 37°C to induce cleavage and heptamerization. To 
reveal surface heptamers, total cell extracts were treated for 10 min at RT with 145 mM 
NaCl and 20 mM MES-Tris, pH 4.5. Protein quantifications were done with the BC 
Assay Protein Quantification Kit from Interchim Uptima (Montluçon, France), 
according to the manufacturer’s protocol.  
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Antibody against PA was from List Biological Laboratories (Campbell, CA), anti-V5 
antibody was from Invitrogen (Carlsbad, CA); anti-actin antibody from Merck Millipore 
(Darmstadt, Germany); anti-Ub antibody (sc-8017) from Santa Cruz Biotechnology Inc. 
(Santa Cruz, CA); anti MARK2 from abnova (Taipei, Taiwan); anti RNF41 was from 
Bethyl Laboratories (Montgomery, TX); anti USP8 was from Cell Signaling (Danvers, 
MA). HRP-conjugated secondary antibodies were from Pierce Chemical Co. (Rockford, 
IL) and Alexa-conjugated secondary antibodies from Molecular Probes (Invitrogen, 
Carlsbad, CA). hCMG2 and hTEM8 hybridomas were generated in our lab. Streptavidin-
agarose conjugated beads were from Sigma-Aldrich (St. Louis, MO), protein G beads 
were from GE Healthcare (Uppsala, Sweden) and HA-beads from Roche (Basel, 
Switzerland);  
 
Immunoprecipitation 
For immunoprecipitation, confluent cells were washed three times with PBS. Cells were 
lysed by incubation for 30 min at 4°C with 0.5% NP-40, 500 mM Tris-HCl, pH 7.4, 20 
mM EDTA, 10 mM NaF, 30 mM sodium pyrophosphate decahydrate, 2 mM 
benzamidine, 1 mM PMSF, 1 mM NEM and a cocktail of protease inhibitors (Roche, 
Basel, Switzerland).  For ubiquitination, 1 mM NEM was added to the buffer. Cell lysates 
were incubated over night at 4°C with antibody and protein G sepharose beads.  
 
Co-immunoprecipitation 
For immunoprecipitation, confluent cells were washed three times with PBS. Cells were 
lysed by incubation for 10 min at 4°C with 0.25% NP-40, 20 mM Tris-HCl, pH 7.4, 1 
mM EDTA, 10% glycerol, 20 mM sodium molybdate, 0.1 mM DTT and a cocktail of 
protease inhibitors (Roche, Basel, Switzerland). Cells were sonicated to complete lysis. 
Cells lysates were incubated over night at 4°C with antibody and the next day for 4 h 
with protein G sepharose beads.  
 
Flow cytometry 
Cells were labeled for 1h at 4°C or for 20 min at 37°C with antibody against the 
extracellular domain of CMG2 (rat 2F6, produced in our lab) or TEM8 (rat 9D1, 
produced in our lab), both diluted 1:2 in IM. Antibody was chased for 2 h at 37°C in 
complete medium. For assays with toxin, cells were starved for 16 h in medium without 
FCS and then treated for 1 h at 4°C with 500 ng/ml PA83  (WT or cleavage-deficient U7 
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mutant) in the antibody/IM mix. Antibody was chased in medium without FCS 
containing 500 ng/ml PA83 (WT or U7). Cells were stained for viability with 
LIVE/DEAD™Fixable Violet Dead Cell Stain Kit (lifetechnologies, Waltham, MA) 
according to the manufacturer’s protocol. Cells were then fixed with BDFix solution 
(BD, Franklin Lakes, NJ) and stained with secondary antibody αrat 647 (Jackson 
ImmunoResearch, West Grove, PA) at 4°C for 30 min. Fluoresence was measured on a 
GalliosTM Flow Cytometer (Beckman Coulter) and data was analyzed with FlowJo 
(Ashland, OR). 
 
Ethical Statement 
Primary human fibroblasts from a control and a Hyaline Fibromatosis Syndrome patient 
were obtained with patient consent, research using these cells was approved by the 
“Commission Cantonale d’éthique de la recherche sur l’être humain” and are registered 
under the approval No A070055 of the Swiss Federal Office of the Environment. 
Patients provided written consent that patient derived cells could be used in any studied 
aimed at a better understanding of Hyaline Fibromatosis Syndrome and the gene 
involved. The patient signed a standard consent form approved by the ethics committee. 
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Results 
 
Internalization of CMG2 is ligand-dependent and requires its multimerization 
The prevailing view has been that CMG2 and TEM8 remain at the cell surface, unless 
the toxin binds, leading to rapid internalization. This has however not directly been 
addressed before. We set up a flow cytometry-based internalization assay, where 
disappearance of the receptor from the PM is measured over time using a specific anti-
receptor antibody.  
 
Figure 1: CMG2 internalization depends on presence of ligand and its multimerization  
A) RpeI cells were labeled for 1 h at 4°C with antibody against the extracellular domain of CMG2. 
Antibody was chased for indicated times at 37°C in complete medium. Cells were stained for viability, 
fixed and stained with secondary antibody at 4°C for 30 min. Fluoresence was measured on a GalliosTM 
Flow Cytometer (Beckman Coulter). B) Patient fibroblasts (CMG2 WT or D50N) were labeled and 
analyzed as described above. Fluorescence at timepoint t=0 was set to 100% for WT and D50N. C) RpeI 
cells were cultivated in complete medium (control), starved for 16h in serum-free medium or starved for 
16 h and recomplemented with 500 ng/ml PAWT during labeling and chase. Cells were labeled and 
analyzed as described above. Fluorescence at timepoint t=0 was set to 100% for all conditions and levels 
after 2h were normalized to the respective levels at t=0. D) RpeI cells were either starved for 16 h in 
serum-free medium (starved) or starved for 16 h and recomplemented with 500 ng/ml PAWT or 500 ng/ml 
PAU7 (non-cleavable toxin mutant) during labeling and chase. Cells were labeled and analyzed as described 
above. Fluorescence at timepoint t=0 was set to 100% for all conditions and levels after 2 h were 
normalized to the respective levels at t=0. 
Statistics were calculated using an unpaired t-test. Errors represent standard deviation. n ≥ 3.  * p≤0.05, ** 
p≤0.01   
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When following CMG2, it was apparent that the protein is lost from the cell surface as a 
function of time, with about 50% internalized after 3 h (Fig.1A). Recent studies have 
revealed that in tissue culture conditions, CMG2 is occupied by a ligand that is either 
present in the serum or synthesized by the cell (Bürgi et al., in preparation). To assess the 
impact of the physiological ligand on the observed internalization of CMG2, we used 
primary fibroblast obtained from a control patient or a patient suffering from HFS and 
harboring the D50N mutation [13]. The aspartic acid at position 50 is part of the Metal 
Ion Dependent Adhesion site (MIDAS) present in the vWA domain, and its mutation 
abolishes the ligand binding capacity. The FACS-based assay was used to compare the 
CMG2 internalization kinetics for both cell lines. While WT CMG2 was internalized as 
observed for Rpe1 cells, CMG2 D50N essentially remained at the surface over a 
timecourse of 4h (Fig.1B). Note this observation also excludes the possibility that the 
observed endocytosis of CMG2 is an artifact of antibody binding.   
We observed that starvation of cells in a serum-free medium liberates CMG2 from its 
physiological ligand. When cells were thus starved for 16 hours in serum-free medium, 
internalization of the WT protein was markedly delayed compared to control conditions 
(Fig. 1C). To exclude that this was an indirect effect of starvation, endocytosis was 
monitored upon addition of PAWT to starved cells. The toxin triggered CMG2 uptake, 
indicating that endocytosis could occur under starvation conditions and thus the lack of 
receptor entry was due to the absence of ligand (Fig.1C). 
Upon binding to the receptor at the cell surface, PAWT undergoes cleavage by furin 
followed by multimerization. The multimer is the pre-pore state and is required for pore 
formation in endosomal membranes and translocation of the enzymatic subunits to the 
cytoplasm. To test whether multimerization of the ligand affects CMG2 uptake, starved 
cells were treated with PAU7, a mutant toxin deficient in the furin cleavage site and 
therefore multimerization-incompetent [25]. This mutant did not lead to significant 
uptake (Fig.1D). Therefore, endocytosis of CMG2 is dependent on the presence and 
binding of ligand as well as the formation of receptor multimers. 
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TEM8 undergoes constitutive endocytosis 
For TEM8, the kinetics of internalization at steady state differs from CMG2. TEM8 
rapidly internalizes roughly 50% of the labeled receptor population in the first hour, with 
a slow internalization rate in the two following hours (Fig.2A).  
 
 
Figure 2: TEM8 undergoes constitutive endocytosis, which is enhanced upon ligand binding  
A) RpeI cells were labeled for 1 h at 4°C with antibody against the extracellular domain of TEM8. 
Antibody was chased for indicated times at 37°C in complete medium. Cells were stained for viability, 
fixed and stained with secondary antibody at 4°C for 30 min. Fluoresence was measured on a GalliosTM 
Flow Cytometer (Beckman Coulter). B) RpeI cells were either starved for 16 h in serum-free medium or 
not. Cells were labeled and analyzed as described above. Fluorescence at timepoint t=0 was set to 100% 
for both conditions and levels after 2h were normalized to the respective levels at t=0. C) RpeI cells were 
starved for 16 h in serum-free medium or not and were then analyzed as in A). D) RpeI cells were either 
starved for 16h in serum-free medium (starved) or starved for 16 h and recomplemented with 500 ng/ml 
PAWT or 500 ng/ml PAU7 (non-cleavable toxin mutant) during labeling and chase. Cells were labeled and 
analyzed as described above. Fluorescence at timepoint t=0 was set to 100% for all conditions and levels 
after 2h were normalized to the respective levels at t=0. 
Statistics were calculated using an unpaired t-test. Errors represent standard deviation. n ≥ 3.  * p≤0.05, ** 
p≤0.01   
 
This was not behavior induced by the temperature switch from labeling at 4°C and 
chasing at 37°C, as receptors labeled for 20 min at 37°C showed the same kinetics (Fig. 
S1). When cells were serum-starved, endocytosis was attenuated compared to control 
conditions (Fig.2B) but still occurred to a significant extent. Therefore, TEM8 undergoes 
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constitutive endocytosis in starved cells but endocytosis is significantly enhanced by the 
presence of ligand (Fig. 2C). Again, only PAWT but not PAU7 accelerated endocytosis in 
starved cells (Fig.2D).  
Thus TEM8, in contrast to CMG2, undergoes ligand-independent, constitutive 
endocytosis. However, endocytosis is enhanced by the binding of the ligand and 
clustering of the receptor. 
 
Identification of novel anthrax toxin receptor interacting proteins 
To find new interaction partners for CMG2, several Yeast Two Hybrid (Y2H) screens 
were performed. The bait used in these screens was either the full-length protein or only 
its cytoskeleton-binding domain (CBD), which is conserved between TEM8 and CMG2 
(Fig.3A) and was shown to interact with the actin cytoskeleton for TEM8 [26]. 
 
Figure 3: RNF41 and MARK2 are new interactors of CMG2 
A) Scheme depicting the general structure of CMG2. CBD is the cytoskeleton-binding domain, conserved 
between TEM8 and CMG2 B) RpeI cells were transfected for 48 h with CMG2-V5 WT. 
Immunoprecipitates against RNF41 or as control unspecific IgGs were analyzed by SDS-PAGE and 
Western Blotting against CMG2-V5 and RNF41. Total cell extracts (TCE) were analyzed for expression 
levels of CMG2-V5. C) RpeI cells were transfected for 48 h with CMG2-V5 WT or ΔCBD. 
Immunoprecipitates against MARK2 or as control unspecific IgGs were analyzed by SDS-PAGE and 
Western Blotting against CMG2-V5. Total cell extracts (TCE) were analyzed for expression levels of 
CMG2-V5. 
The first hit from a membrane Y2H with the full length CMG2 as bait, was the E3 
ubiquitin ligase RNF41 (Nrdp1), an enzyme involved in the trafficking and 
downregulation of cell surface receptors. RNF41 could be co-immunoprecipitated with 
CMG2 WT (Fig.3B). From a Y2H screen in which the CBD was used as bait, the only 
hit was the serine/threonine kinase MARK2 (Par1b). This kinase is involved in 
regulating polarity [27] but was more recently also shown to phosphorylate and activate 
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RNF41 [28]. Again, MARK2 could be co-immunoprecipitated with CMG2 WT, but this 
time, as expected, not with the mutant lacking the CBD domain (Fig.3C). Thus, both 
RNF41 and MARK2 appear to be novel interactors of CMG2.  
 
The first step of endocytosis of CMG2 is regulated by RNF41 
To test for functional interaction of these novel interactors with CMG2 and TEM8, 
expression of the receptor at the surface as well as endocytosis rates were measured in 
the presence or absence of the proteins. Here we also included Cbl, the previously 
identified E3 ligase of TEM8 [9] and USP8, the deubiquitinating enzyme related to 
stability and function of RNF41 [29, 30] in our analysis.  
   
 
Figure 4: RNF41 mediates early steps of CMG2 endocytosis 
A) RpeI cells were transfected for 72 h with control siRNA (control) or with siRNA against Cbl, MARK2, 
RNF41 or USP8. Cells were labeled for 1 h at 4°C with antibody against the extracellular domain of 
CMG2 and steady state PM expression of CMG2 was assessed directly without chase. Cells were stained 
for viability, fixed and stained with secondary antibody at 4°C for 30 min. Fluoresence was measured on a 
GalliosTM Flow Cytometer (Beckman Coulter). Fluorescence at timepoint t=0 was set to 100% for WT and 
levels for all other conditions were normalized to WT. B) RpeI cells were transfected for 72 h with control 
siRNA (control) or with siRNA against Cbl, MARK2, RNF41 or USP8. Cells were labeled for 1 h at 4°C 
with antibody against the extracellular domain of TEM8. Cells were treated and analyzed as in A) C) RpeI 
cells were transfected for 72 h with control siRNA (control) or with siRNA against Cbl, MARK2, RNF41 
or USP8. Cells were labeled for 1 h at 4°C with antibody against the extracellular domain of CMG2. 
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Antibody was chased for 2 h at 37°C in complete medium. Cells were stained for viability, fixed and 
stained with secondary antibody at 4°C for 30 min. Fluoresence was measured on a GalliosTM Flow 
Cytometer (Beckman Coulter). Fluorescence at timepoint t=0 was set to 100% for all conditions and levels 
after 2 h were normalized to the respective levels at t=0. D) RpeI cells were transfected for 72 h with 
control siRNA (control) or with siRNA against Cbl, MARK2, RNF41 or USP8. Cells were labeled for 1 h 
at 4°C with antibody against the extracellular domain of TEM8. Cells were treated and analyzed as in C). 
Statistics were calculated using an unpaired t-test. Errors represent standard deviation. n ≥ 3.  * p≤0.05, ** 
p≤0.01, *** p≤0.001   
 
Knockdown efficiencies for all proteins were either confirmed by Western Blot or qPCR 
(Fig. S2A-C) or had been established previously for Cbl [9]. Silencing of any of the four 
proteins led to an increase of the steady state level of CMG2 at the cell surface (Fig.4A). 
For TEM8 however, only loss of Cbl and USP8 led to an elevated surface expression 
compared to control cells (Fig.4B).  
An elevation in surface levels could be caused by a defect in endocytosis. However, 
CMG2 was more stable at the cell surface over time only when cells were depleted of 
RNF41 (Fig.4C). Endocytosis of TEM8 was not affected by the absence of all four 
proteins (Fig.4D). Therefore, only RNF41 controls physiological endocytosis of CMG2. 
The increase in surface expression for the other proteins might be explained by a defect 
in later steps of endocytosis, a long-term accumulation not measurable in the timecourse 
assessed here or a difference in recycling. 
 
RNF41, MARK2, Cbl and USP8 affect anthrax toxin entry via CMG2 
To assess endocytosis with the pathological ligand PA, we turned to a well-established 
assay for toxin binding and entry into cells [6, 7]. Three parameters can be monitored: 1) 
the binding of PA and its conversion for the 83 (PA83) to the 63 kDa (PA63) form, 2) the 
appearance of the SDS-resistant multimeric PA, which only forms once the PA multimer 
has undergone the conformational change leading to membrane insertion (Inserted 
PA7mer) and 3) the total PA multimer (Total PA7mer), which can be visualized by acidifying 
cell extracts in order to induce the conversion to the SDS-resistant for all PA multimers 
(note that PA multimerizes at the cell surface but that this multimer is SDS-sensitive and 
thus migrates as a monomer). Cells expressing only the main anthrax receptor CMG2 
(RpeI shTEM8) were treated for different timepoints with toxin, either in the presence 
or absence of our protein of interest  (Fig.5A and B).   
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Figure 5: RNF41, MARK2, Cbl and USP8 affect anthrax toxin entry via CMG2 
A) Scheme of toxin entry indicating the different steps that can be monitored in this assay B) 
Experimental setup for the toxin entry assay C) RpeI shTEM8 cells were either transfected for 48h with an 
control plasmid without insert (empty) or with a dominant-negative form of RNF41 (RNF41 DN) before 
toxin entry. Knockdowns for RNF41 DN has been established previously [23]. Cells were treated for 1 h at 
4°C with 500 ng/ml PA83 and shifted to 37°C for indicated times to induce cleavage and heptamerization. 
Proteins were quantified and 40 μg were loaded on 4-20% gradient SDS-PAGE gels and blotted against 
PA, CMG2 and actin (equal loading control). To visualize SDS-sensitive heptamers (surface heptamers), 
samples were treated with 145 mM NaCl and 20 mM MES-Tris, pH 4.5 for 10 min at RT before loading 
on the gel. 
 D)-F) RpeI shTEM8 cells were transfected for 72 h with control siRNA (control) or with siRNA against 
MARK2, Cbl or USP8 before toxin entry. Cells were treated as described for C). 
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For cells transfected with a dominant-negative form of RNF41, both endogenous levels 
of CMG2 as well as binding and cleavage efficiency of PA were comparable to the 
control cells. Heptamer insertion in endosomes was impaired, but not formation at the 
surface (Fig.5C). Absence of MARK2 results in a slight defect in surface formation and a 
strong inhibition of internalization for CMG2 (Fig.5D). Cells depleted of Cbl showed a 
decrease in both surface as well as inserted heptamers. This suggests that formation of 
the heptamer was inhibited, yet whatever heptamer was formed could efficiently enter 
the cells (Fig.5E). For cells lacking USP8, a striking increase in total protein 
concentration of CMG2 was observed. This increase was also reflected in the amount of 
PA bound to the receptor, as PA83 and PA63 were elevated. Yet both inserted and total 
heptamer were decreased compared to control cells (Fig.5F). Altogether these 
observations indicate that Cbl influences the surface distribution of CMG2, and thereby 
multimerization kinetics of PA, while RNF41 and MARK2 regulate PA-induced CMG2 
endocytosis. USP8 has a more general effect, affecting surface expression and 
distribution and possibly also endocytosis. 
 
MARK2 acts on both receptors to mediate internalization 
To test the involvement of MARK2 and USP8 in toxin entry via TEM8, the same 
experiments were performed on RpeI shCMG2, cells that only express TEM8. 
 
Figure 6: MARK2 also affects entry of anthrax toxin via TEM8  
A) RpeI shCMG2 cells were transfected for 72 h with control siRNA (control) or with siRNA against 
USP8 before toxin entry. Cells were treated for 1 h at 4°C with 500 ng/ml PA83 and shifted to 37°C for 
indicated times to induce ubiquitination. Proteins were quantified and 40 μg were loaded on 4-20% 
gradient SDS-PAGE gels and blotted against PA, CMG2 and actin (equal loading control). To visualize 
SDS-sensitive heptamers (surface heptamers), samples were treated 145 mM NaCl and 20 mM MES-Tris, 
pH 4.5 for 10 min at RT before loading on the gel. B) RpeI shCMG2 cells were transfected for 72 h with 
control siRNA (control) or with siRNA against MARK2 before toxin entry. Cells were treated for 1 h at 
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4°C with 500 ng/ml PA83 and shifted to 37°C for indicated times to induce ubiquitination. 
Immunoprecipitates against TEM8 were analyzed by SDS-PAGE and Western Blotting against ubiquitin, 
PA and actin (equal loading control). 
 
As for CMG2, silencing of USP8 led to a strong increase in TEM8 protein levels, and a 
consistent increase in PA (Fig.6A). In contrast, multimerization (Total PA7mer) and 
endocytosis (Inserted PA7mer) were not inhibited but appeared increased, consistent with 
the increased toxin binding (Fig.6A).  
In cells depleted of MARK2, levels of TEM8, as well as PA binding and cleavage were 
not changed. However, there was a decrease in heptamer formation and endocytosis 
(Fig.6B), comparable to the results of CMG2 (Fig.5D). MARK2 seems to be a conserved 
regulator of toxin entry, whereas USP8 impacts only on toxin entry via CMG2. 
 
Differential E3 ligase requirement of CMG2 and TEM8 
Cbl has been established as the E3 ligase for TEM8 and mediates entry by ubiquitination 
of the receptor after toxin binding [7, 9]. The involvement of Cbl in CMG2-mediated 
endocytosis has not been addressed and the present identification of RNF41 as a protein 
interacting with CMG2 raises the interesting possibility that despite their high level of 
sequence similarity, TEM8 and CMG2 have different requirements in terms of E3 
ligases. To test this possibility, PA induced receptor ubiquitination was tested for both 
CMG2 and TEM8 in cells that express either one or the other receptor. 
 
 
Figure 7: RNF41 is specific for CMG2 but not for TEM8 
A) RpeI shTEM8 cells were transfected for 72h with control siRNA (control) or with siRNA against Cbl 
or RNF41 before toxin entry. Cells were treated for 1h at 4°C with 500 ng/ml PA83 and shifted to 37°C 
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for indicated times to induce ubiquitination. Immunoprecipitates against CMG2 were analyzed by SDS-
PAGE and Western Blotting against ubiquitin, PA and actin (equal loading control). B) RpeI shCMG2 
cells were transfected for 72h with control siRNA (control) or with siRNA against Cbl or RNF41 before 
toxin entry. Cells were treated for 1h at 4°C with 500 ng/ml PA83 and shifted to 37°C for indicated times 
to induce ubiquitination. Immunoprecipitates against TEM8 were analyzed by SDS-PAGE and Western 
Blotting against ubiquitin, PA and actin (equal loading control). 
 
After toxin treatment under control conditions, over time both CMG2 and TEM8 will 
undergo PA-induced ubiquitination, which is absent at steady state (Fig.7A and B). In the 
absence of Cbl or RNF41, this ubiquitination is abolished after toxin binding for CMG2 
(Fig. 7A). Additionally, a marked decrease in inserted heptamers can be observed, 
consistent with previous results (Fig.5C and E).  
Silencing of Cbl strongly affects the ubiquitination of TEM8 and the formation of the 
SDS-resistance PA heptamer, as expected, while silencing of RNF41 has no effect (Fig. 
7B). Thus, Cbl can modify the ubiquitination of both receptors, whereas RNF41 is 
specific for CMG2. 
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Discussion 
 
Both CMG2 and TEM8, apart from their role as anthrax toxin receptors, serve 
important roles in their physiological context. This is evident from the two severe genetic 
diseases that are linked to mutations in these proteins, either HFS for CMG2 or GAPO 
syndrome for TEM8 [22, 31]. Here we apply new methods to investigate endocytosis, 
steady state kinetics and physiological behavior of these two interesting proteins and we 
identify new potential interactors of these receptors.  
 
Physio log i cal  endocytos is  o f  CMG2 and TEM8 
We show, for the first time, that both receptors also internalize without their pathogenic 
ligand, although at very different rates. In the case of CMG2, this internalization is 
completely dependent on the presence and binding of a physiological ligand. 
Additionally, it seems that internalization only occurs if the ligand induces the 
multimerization of the receptor. In the absence of ligand or if this ligand fails to cluster 
the receptor, CMG2 remains at the cell surface. This is a concept that was already shown 
for the Transferrin receptor, where clustering promotes endocytosis [32]. Interestingly, 
the internalization kinetics of TEM8 differs drastically from those of CMG2. It appears 
that although the same concepts as described for CMG2 also apply for half of the TEM8 
population, the other half internalizes constitutively. This means that potentially only 
50% of the receptor present at the cell surface actually can engage in binding to a ligand 
whereas the other half cannot. It has been suggested before that TEM8 exists in two 
forms at the PM, in an open or closed conformation, similar to integrins [33]. We already 
know that in the absence of ligand binding, both CMG2 and TEM8 can bind actin [7 and 
L.Abrami, personal communication]. Binding of ligand will release this interaction [34]. 
In cells endogenously expressing CMG2 and TEM8, only TEM8 shows interaction with 
actin, suggesting that a majority of CMG2 is always bound to ligand whereas TEM8 is 
not. Our biphasic internalization curve could reflect this distribution. CMG2, on the 
other hand, is constantly internalized but at a slower rate, suggesting a more 
homogeneous population of receptor at the cell surface.  
The internalization cue so far is not understood. If indeed CMG2 binds to collagen VI, 
as studies from our lab and others suggest, the question arises as to why and when the 
receptor internalizes and if the ligand internalizes at the same time. If CMG2, like 
integrins, coordinates adhesion, a possibility could be that endocytosis is triggered 
dependent on adhesion strength. For E-cadherin it was shown that large clusters of the 
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protein are targeted preferentially for endocytosis, thereby keeping adhesion strength 
equilibrated over time [35]. 
 
Novel  regulators o f  anthrax toxin entry 
In this study four new proteins acting on toxin entry via CMG2 were identified, of which 
two are shared with the pathway via TEM8.  We have started to understand their mode 
of action on the intricate and highly regulated entry of anthrax toxin. 
Both RNF41 and MARK2 affect internalization of the PA-CMG2 heptamer after toxin 
binding but only RNF41 also affects physiological endocytosis of CMG2. A recent paper 
suggests a model in which RNF41 activity depends on phosphorylation by MARK2 [36]. 
We show that internalization of toxin via TEM8 is also controlled by MARK2 but is 
completely independent of RNF41. This argues that apart from acting on RNF41, in our 
case MARK2 must have an additional, potentially direct effect on our receptors. This is 
strengthened by the fact that MARK2 was found in a Yeast-2-Hybrid screen with the 
CBD, a conserved cytosolic domain of CMG2 and TEM8. We have so far not been able 
to identify if MARK2 phosphorylates CMG2 and TEM8 directly. It could be that 
although the physical interaction is direct, the functional interaction between MARK2 
and the receptors might not. Two studies have already placed MARK2 in the context of 
clathrin-mediated endocytosis. It can be co-purified with clathrin-coated vesicles and 
might facilitate their assembly [37] and seems to promote vesicle transport along 
microtubules [38]. One could imagine both possibilities for our case, which will be 
addressed in the future.  
 
Cbl was already identified as the E3 ubiquitin ligase of TEM8 mediating endocytosis in 
an earlier study from our lab [9]. We now show that Cbl, together with RNF41 is also 
involved in the pathway of toxin uptake via CMG2. Interestingly, Cbl seems to have a 
different effect on CMG2 than TEM8. Whereas ubiquitination of TEM8 by Cbl 
regulates the internalization step [7], it mediates heptamer formation for CMG2. The 
internalization process of CMG2 in turn is regulated by RNF41, a protein, which is 
completely dispensable for toxin entry via TEM8. CMG2 therefore needs ubiquitination 
by two different E3 ligases to successfully enter after toxin binding. The two enzymes 
might act in concert, with Cbl starting to ubiquitinate the receptor, which promotes its 
heptamerization. Then, RNF41 could add on to the existing ubiquitin chain, either just 
extending it or by adding a differently linked chain. It could be that the extension of the 
 83 
chain reaches a threshold required for endocytosis or that the signal consists of a 
differently linked ubiquitin chain. It is also interesting to note that TEM8 only seems to 
need one single E3 ligase, although we cannot completely exclude the possibility of 
another enzyme. 
 
The last protein that was identified was USP8, a deubiquitinating enzyme. Two studies 
link USP8 to RNF41. The proteins mediate each other’s stability and thus regulate 
receptor trafficking [29, 30]. But more famously, USP8 is known as a DUB associated 
with the ESCRT-0 complex at endosomes. There it deubiquitinates cargo and 
components of ESCRT-0, which can lead to degradation or recycling of this cargo and 
stabilization of the ESCRT complex, thereby maintaining normal endosome morphology 
and function [39-43]. Here a loss of USP8 only has an impact on toxin entry via CMG2 
but not TEM8. If indeed USP8 and RNF41 are in the same pathway, this would be 
consistent with RNF41 only acting on CMG2 but not TEM8. Another possibility is that 
USP8’s effect on early endosome dynamics might play a role in toxin entry as well. This 
could explain why the effect is limited to CMG2. To form a pore, PA needs to undergo a 
conformational change linked to the change in pH in endosomes. When PA is bound to 
TEM8, the pH requirements are already met in early endosomes, whereas if it is bound 
to CMG2, it needs to progress to later endosomes and their lower pH [44]. So even 
though here we show that overall receptor levels of CMG2 and TEM8 are elevated after 
knockdown of USP8, arguing for a misbalance of receptor turnover at the level of early 
endosomes during siRNA treatment, pore formation is only inhibited for CMG2.  
This work sheds light on the endocytosis of the two anthrax toxin receptors, both in the 
presence and absence of its surrogate ligand anthrax toxin. For the first time, steady state 
behavior of CMG2 and TEM8 has been assessed and novel regulators of both 
pathological and physiological endocytosis of the two receptors were identified. Our 
results add crucial information to the research on the physiological function of CMG2 
and TEM8. 
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Supplementary Figures 
 
 
 
Figure S1: Internalization kinetics with different labeling times 
A) RpeI cells were labeled for either 1 h at 4°C or for 20 min at 37°C with antibody against the 
extracellular domain of CMG2. Antibody was chased for indicated times at 37°C in complete medium. 
Cells were stained for viability, fixed and stained with secondary antibody at 4°C for 30 min. Fluoresence 
was measured on a GalliosTM Flow Cytometer (Beckman Coulter). B) RpeI cells were labeled for either 1 h 
at 4°C or for 20 min at 37°C with antibody against the extracellular domain of TEM8 and were labeled and 
analyzed as described above.  
 
 
 
 
 
Figure S2: Control of knockdown for RNF41, USP8 and MARK2 
RpeI cells were transfected for 72 h with control siRNA (ctrl) or with siRNA against MARK2, RNF41 or 
USP8 before toxin entry. A) Proteins were quantified and 40 μg were loaded on 4-20% gradient SDS-
PAGE gels and blotted against RNF41 and actin (equal loading control). B) qPCR analysis was performed 
with specific primers against MARK2 and housekeeping genes as a control. n=3 C) Proteins were 
quantified and 40 μg were loaded on 4-20% gradient SDS-PAGE gels and blotted against USP8 and actin 
(equal loading control). 
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III. Conclusions and perspectives 
 
In this work, we have investigated folding and endocytosis of the two anthrax toxin 
receptors CMG2 and TEM8. Both receptors, apart from their crucial role in anthrax 
pathogenesis, are also indispensable in a physiological context. Mutations in cmg2 lead to 
Hyaline Fibromatosis Syndrome, whereas mutations in tem8 are associated with GAPO 
syndrome. The physiological role of the two receptors to date remains elusive and 
knockout mice for either CMG2 or TEM8 have so far only been able to recapitulate 
limited aspects of the respective disease. Therefore, it is imperative to investigate the role 
of these two important proteins in more detail. In this thesis I presented two research 
projects and will integrate the findings into the big picture of CMG2 and TEM8 
research. 
 
N-glycosylation of anthrax toxin receptors CMG2 and TEM8 
 
N-glycosylation is a common posttranslational modification, which has been shown to 
be important for protein folding for a wide variety of substrates. We found that both 
CMG2 and TEM8 are glycosylated on their predicted sites and this is advantageous for 
folding and function of the proteins.  
The role of glycosylation for CMG2 is especially intriguing, as it only seems to become 
important when other protein-destabilizing mutants are present. In this case, 
glycosylation acts as a buffer and increases folding efficiency for the mutants. It would be 
interesting to know if these mutants have an increased occupancy in glycosylation or are 
differentially glycosylated compared to the WT protein.  
Another interesting aspect to understand would be why two proteins that are so closely 
related as CMG2 and TEM8 vary so substantially in their dependence on N-
glycosylation. Even the glycosylation site in the Ig-like domain of the two proteins is 
conserved, but loss of this site affects CMG2 and TEM8 very differently.  
We have not been able to assess the variation in folding efficiency of CMG2 and TEM8. 
Despite the high sequence similarity it seems that TEM8 presents crucial sequence 
alterations responsible for its higher tendency to misfold. So far, we have always 
considered CMG2, even WT, to be a protein that frequently fails to fold. This stems 
from our observations that a high number of known HFS mutations leads to misfolding 
of the protein and subsequent loss-of-function [2]. The genotype-phenotype correlation 
for GAPO syndrome is far less developed. It will therefore be interesting to see if 
mutations seen in GAPO syndrome are also highly correlated with the misfolding of 
TEM8 and which domains of the protein are most mutation-prone.  
This work sheds light on the folding of the two anthrax toxin receptors and reveals 
unexpected, yet intriguing, differences between these two closely related receptors.   
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Behavior and distribution at the plasma membrane 
 
After being synthesized, CMG2 rapidly travels to the plasma membrane. There, it 
encounters its ligand and will bind to it. This binding leads to a signal transduction that 
ultimately leads to the release of the actin cytoskeleton from the cytosolic tail (J. Bürgi, 
unpublished work). 
 
 
Fig .12 Graphi ca l  summary o f  a c t in  b ind ing  and re l ease  CMG2 binds actin via talin and vinculin 
with its cytosolic tail at the plasma membrane if not bound to a ligand. Binding of a ligand to the extracellular 
domain of CMG2 leads to a release of actin, talin and vinculin. This action is mediated by Src phosphorylating 
CMG2.  
 
Binding of the ligand to CMG2 will lead to a constant internalization of the receptor. 
This is dependent on the clustering of the receptor into multimers, as binding alone 
cannot restart endocytosis (Fig. 1D of the draft manuscript). This is interesting, as it 
implies that either CMG2 will actively segregate into clusters after binding or that the 
ligand can mediate this aggregation. It was shown that CMG2 can form homodimers and 
an extended FRAP method in collaboration with the lab of Gerhard Schütz (TU Vienna) 
showed that around 30% of CMG2 is present as a dimer at the cell surface (S. Blaskovic, 
unpublished results). It is possible that CMG2 is preorganized in dimers at the cell 
surface and that binding of a ligand leads to the formation of higher order clusters, which 
are then endocytosis-competent. Interestingly, TEM8 can self-associate though its TM 
domain and mutations in this domain block interaction and slow down heptamerization 
after toxin binding [322], nicely backing our hypothesis. 
For the binding of PA, we already know that endocytosis requires the toxin-receptor 
complex to be heptameric, as single receptors, even when bound to the toxin, will not 
internalize. This preorganization and the fact that clustered receptors internalize 
preferentially, was already shown for the EGFR [323]. As CMG2 is a receptor without 
enzymatic activity, the question as to how signal transduction is achieved remains 
puzzling. The cytoplasmic tail of CMG2 could be a mediator in this process as it has 
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been described as a highly disordered domain [9]. After binding of a ligand to the 
extracellular domain, we could envision a conformational change of the tail, which would 
allow for binding of a different set of proteins. This creates two sets of “signaling hubs” 
for either a ligand-free or ligand-bound receptor, a concept that has been described for 
numerous proteins with disordered domains [324-326]. Another option is that the 
conformation of the tail could be involved in the organization of CMG2 at the PM, 
either confining it to monomers or mediating association into dimers or oligomers. A 
similar concept was shown for STIM1 in response to intracellular Ca2+ levels [327]. 
Interestingly, the steady-state endocytosis of CMG2 is a rather slow process (Fig. 1A of 
the draft manuscript) compared to endocytosis triggered by PA. Yet we know that a 
majority of the receptor is occupied with ligand at steady state (J. Bürgi, unpublished 
results). Potentially, clustering of CMG2 with the physiological ligand into multimers that 
can internalize correctly is a slow process that reflects the slow kinetics of endocytosis at 
steady state. PA, which has a higher affinity to CMG2 than the physiological ligand, 
might be able to speed up this process, thereby leading to a faster endocytosis rate. The 
concept that ligand can modulate entry speed has been recently proposed for the 
cannabinoid receptor 1, a GPCR [328].  
For TEM8, we see a much faster initial drop in surface fluorescence than for CMG2 
(Fig.2A of the draft manuscript). After this, the population at the surface seems to be 
declining much slower. This suggests the presence of two populations: one that can bind 
ligand and is regulated by this, similar to CMG2, and one that cannot bind ligand and 
therefore traffics ligand-independently. This might depend on our experimental setup. 
CMG2 and TEM8 not necessarily bind to the same ligand and it is unclear, to what the 
receptors are bound in cell-culture conditions. It could be interesting to test different 
conditions to find out more about the heterogeneity of TEM8 at the cell surface. 
Recent experiments from our lab suggest that CMG2, when bound to ligand also binds 
to RhoA with its cytoplasmic tail (J. Bürgi, unpublished results). This indicates a 
competitive binding between either actin via talin and vinculin for “non-activated” e.g. 
ligand-free receptor and RhoA for “activated”, e.g. ligand-bound receptor. CMG2 could 
be pre-organized by the actin cytoskeleton and could be re-arranged into spatially and 
functionally different clusters by RhoA, once activated by a ligand. This link with RhoA 
is evolutionary conserved. In zebrafish, binding of Antxr2a, the CMG2 homologue, to 
actin and RhoA mediates the mitotic spindle positioning [28]. For the moment it is 
unclear how this function in zebrafish could be translated to humans. A separate analysis 
of these two populations is challenging. By a long-term perturbation of RhoA, i.e. by 
siRNA treatment, the entity of the actin cytoskeleton would be affected, making it 
difficult to differentiate between the effects caused by actin loss or RhoA loss. One 
possible experiment to circumvent this would be a very short-term perturbation of RhoA 
with the “knock-sideways” technique [329], where the protein of interest is segregated 
away from its normal localization. 
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Regulation of endocytosis of CMG2 and TEM8 
 
Once inside the endosomal pathway, the default destination for receptors is recycling 
back to the plasma membrane. The decision between recycling and degradation can be 
dependent on the concentration of the ligand as for EGFR [330] but might also be 
determined by affinity of the ligand.  
 
 
 
Fig .  13 Descr ip t ion  and repres en ta t iv e  r e su l t  o f  a  pro t ease -pro t e c t ion  assay  CMG2 with a V5 
tag at its C-terminus (red star) is expressed in cells. The tag is sensitive to trypsin digestion after fractionation and 
enrichment of endosomes, when present in early endosomes (EE). It becomes protected from trypsin by inclusion 
into intraluminal vesicles in late endosomes (LE). This can be assessed by Western Blot. PA63 is always inside 
the endosomes, where it is continuously protected from trypsin treatment. 
  
After the addition of toxin to the cells, we can see CMG2 in multivesicular endosomes 
already after a short time. A trypsin-resistant band appears in a protease protection assay 
(see above) and our toxin assays show similar results. For toxin bound to CMG2 this 
ensures that the receptor faithfully transports its pathological cargo to late endosomes 
where pore formation can occur. It would be interesting to test this also without toxin. 
PA could lead to a different or at least faster trafficking route of the receptor. A 
modification of the pathway would not be necessary for TEM8, as toxin associated to 
this receptor can already insert into the membrane of early endosomes. 
A possible way of changing the fate of the receptor after internalization is a change in 
post-translational modifications. This might depend on which ligand is bound. When we 
look at ubiquitination after adding PA to the cells, we see the apparition of a long smear, 
consistent with the receptor being rapidly polyubiquitinated after toxin binding (Fig.7 of 
the draft manuscript). However, at steady state, this ubiquitination is mostly absent. This 
suggests that physiological endocytosis is regulated differently or with a lower level of 
polyubiquitination that we are unable to detect. 
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Fig .  14 Schemat i c  o f  the  thre sho ld -media t ed  mode l  fo r  EGFR endocy tos i s  Depending on the 
concentration of the ligand, EGFR will be either routed to CME and recycling, or mostly to CIE (or here NCE) 
and degradation. This depends on the level of phosphorylation, which controls the levels of ubiquitination. Higher 
levels of phosphorylation allow stable binding of Cbl and this in turn controls the levels of ubiquitination. Figure 
from [331] 
This threshold model has already been proposed for the EGFR, where also the level of 
ubiquitination depends on the concentration of the ligand and this in turn regulates 
receptor fate [332]. Interestingly, this difference in ubiquitination also depends on the 
level of phosphorylation, a modification which also occurs in CMG2 and TEM8 after 
toxin binding [201].  
Events after endocytosis 
In the case of PA, the pathological ligand stays attached to the receptor and hitchhikes 
into the cell. We do not know if this is also the case for the physiological ligand. If the 
ligand is indeed, as shown from ours and other labs, collagen VI, it would be important 
to determine how this could be achieved. Collagen VI is a large protein, a fibrillar 
collagen, for which very little is known about its turnover. One report states that it is 
taken up by phagocytosis, followed by degradation in lysosomes [333]. Other collagens, 
such as collagen I, II, IV and V, can be internalized by the endocytic collagen receptor 
uPARAP/Endo180 and are degraded in the lysosome [334, 335]. Therefore, a scenario, 
in which collagen VI, or fragments of it are endocytosed with CMG2 and subsequently 
degraded, thereby regulating its turnover, can be envisioned. The accumulation of 
collagen VI in HFS patients and also in CMG2 knockout mice also strongly argues for a 
dysregulation of collagen VI turnover. We would need to test if indeed collagen VI can 
be taken up into cells and is capable of restarting endocytosis of CMG2 in starved cells, 
thereby acting as a bona fide ligand.  
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Another question we have started to address is the signal transduction after binding and 
internalization of the receptor. Even though CMG2 and TEM8 are cell surface receptors 
without intrinsic enzymatic activity, they might be able to indirectly convey signals to a 
downstream signaling pathway. We therefore used a commercially available 
phosphokinase assay to look at potential upregulation after ligand binding. 
 
 Fig .  15 PA binding  and endocy tos i s  a c t iva t e s  pro t e ins  invo lved  in  ac t in  r earrangement A) Fibroblasts 
were starved for 16h in serum-free medium and were treated for 1h at 4°C with 500ng/ml PAWT or 500ng/ml PAU7 (non-
cleavable toxin mutant). Cells were shifted to 37°C for 10 min to induce cleavage and heptamerization. Proteins were 
quantified and 350 μg were used for each membrane set. In red are proteins that came up several times B) Quantification of 
control fibroblasts. As a cutoff, 120% in signal increase was used. 
 
When we measured the phosphorylation of the 43 substrates detectable in the kit and 
compared levels between PAWT- and PAU7-treated cells, we indeed found some 
interesting hits (see above). A target that was significantly upregulated in all three assays 
was the non-receptor tyrosine kinase Fgr, a member of the Src subfamily. It has been 
implicated in transmitting signals downstream of plasma membrane proteins lacking 
kinase activity, such as ?2 integrin signaling [336]. This in turn affects cytoskeletal 
structure and rearrangements, both of the actin cytoskeleton in general and in focal 
adhesions [337]. Another hit was PLC?1, which was only present in two out of three 
assays, but was the most highly elevated one in cells with both receptors. This enzyme is 
a PI(4,5)P2 diesterase, producing diacylglycerol and IP3 and has again been implicated in 
actin reorganization [338]. Among the upregulated targets found in one or two assays 
also functionally linked to the actin cytoskeleton were PYK2 (focal adhesion kinase 2) 
and Hck, also a non-receptor tyrosine kinase.  
CMG2 was found in a proteomics study to be present in focal adhesions [339] and its 
functional relationship with proteins such as talin and vinculin (J.Bürgi, unpublished 
results) also places it in this cellular environment. It would therefore be intriguing to see 
if the dynamics of focal adhesions are altered in response to toxin entry. 
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Role of partner proteins in endocytosis of CMG2 and TEM8 
 
In this work, we identified four new proteins that mediate entry of anthrax toxin into 
cells, namely RNF41, MARK2, Cbl and USP8. Cbl and MARK2 also mediate entry via 
TEM8. The model we propose is the following: 
 
Fig .  16 Graphi ca l  abs t rac t  o f  par tner  pro t e ins  r egu la t ing  the  l i f e cy c l e  o f  CMG2 CMG2 will 
be ubiquitinated upon ligand binding by Cbl, promoting heptamerization. Clustered CMG2 will be further 
ubiquitinated by RNF41, leading to endocytosis. At the early endosome, the receptor fate is decided. De-
ubiquitination by USP8 leads to CMG2 being routed to late endosomes, where degradation of the receptor can 
occur. The exact role of MARK2 in this process remains unclear. 
 
CMG2 is ubiquitinated by Cbl to promote heptamerization after ligand binding. Further 
ubiquitination by RNF41 mediates endocytosis of the multimeric ligand-receptor 
complex. At the endosome, deubiquitination of CMG2 could mediate either targeting to 
the recycling pathway or to late endosomes. This could be done by USP8, although this 
is a possibility that we still are adressing. We have not been able to pinpoint the exact 
step of endocytosis that MARK2 controls. 
It is interesting to note that CMG2 seems to need two E3 ligases for an efficient entry 
after toxin binding. Cbl has been shown to mediate both mono- and polyubiquitination 
of receptors [340]. Our experiments show the apparition of a smear of ubiquitinated 
?96 
CMG2 after toxin binding (Fig.7 of the draft manuscript), more consistent with 
polyubiquitination. RNF41 seems to lead to the polyubiquitination of its substrates, 
including itself [231, 341]. In our case, we could envision a scenario in which Cbl 
ubiquitinates CMG2 after toxin binding, promoting heptamerization. After this, RNF41 
adds on to the ubiquitination on K350, reaching a threshold, which allows endocytosis 
and efficient targeting to the late endosomes. In the absence of toxin, only RNF41 seems 
to be required for endocytosis of CMG2. Potentially, this leads to a different 
ubiquitination pattern, also changing the fate of the receptor and promoting recycling 
instead of degradation. Although K350 seems to be the main ubiquitination site of 
CMG2 [202], we cannot exclude the possibility of other sites being ubiquitinated. This 
other ubiquitination might be too low for our methods to detect or is transient and 
therefore hard to capture. The conserved site in TEM8, K352, is the main, but not the 
only site of ubiquitination [202]. 
So far, we have not been able to show direct interaction between CMG2 and USP8. 
Nevertheless, it is possible that CMG2 is deubiquitinated by USP8 and this can promote 
the decision of recycling or degradation. Such a mechanism has been shown for USP8 
and EGFR, where deubiquitination of EGFR by USP8 facilitates the sorting of the 
receptor to MVB with the help of the ESCRT complexes [241, 243, 245]. On the other 
hand, it is also possible for our effect being based on generally changed endosome 
dynamics, which have been observed for cells deficient in USP8 [149].  
So far it is unclear, how MARK2 affects the endocytosis of anthrax toxin both via 
CMG2 and TEM8. The fact that MARK2 was identified in a Yeast Two Hybrid screen 
with a domain conserved between CMG2 and TEM8 argues for a direct interaction. 
However, we have not been able to show that phosphorylation of a serine or threonine 
residue in the cytosolic domain of the two receptors is involved in toxin entry. Therefore, 
it is possible that the effect of MARK2 is indirect and via a different interaction partner. 
 
Integration of our data into a general model for function of CMG2 
 
Research on CMG2 has led to a basic understanding of the function of this protein. 
However, more information is needed to enhance our knowledge about this important 
receptor.  
The two main aspects of CMG2 that come up repeatedly are angiogenesis and binding to 
the extracellular matrix. How these two relate to each other is unclear. CMG2 was found 
in an in vitro screen for capillary formation. It was among the most upregulated genes in 
early capillary formation, i.e. during a specific point in capillary development [1]. The 
same is true for TEM8, which seems to be needed only during developmental or 
pathological angiogenesis [17]. To the best of our knowledge, there are no defects in 
angiogenesis in HFS patients. Data from a collaboration with the lab of Tatiana Petrova 
(Unil, Lausanne) however suggest a defect in correct lymph vessel formation in CMG2 
knockout mice.  
For TEM8, the link between vascular and fibrotic phenotypes is easier to understand. A 
recent paper links both vascular and connective tissue homeostasis to regulation by 
TEM8 [342]. Also, TEM8 was shown to interact with VEGFR2 in infantile 
hemangiomas [343] and finally, GAPO patients show both an accumulation of ECM 
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components as well as venous malformations and vascular abnormities [47, 344]. It 
seems that TGFβ1 signaling contributes to the profibrotic phenotype in TEM8 knockout 
mice [342]. Data from our lab also suggests that TGFβ signaling is linked to CMG2 
(J.Bürgi, unpublished results). Although all this points in the same direction, further 
studies are needed to decipher the exact pathway at the molecular level. 
 
In the context of binding to the extracellular matrix, our work adds important 
information to this process. We now know that both receptors internalize constantly. 
CMG2 internalizes rather slowly, with a homogenous population distribution. TEM8 
however seems to have two distinct populations, that show distinct kinetics. Endocytosis 
is ligand-binding and multimerization dependent, two features that are most probably 
also true in the physiological context. It will now be crucial to assess the behavior of the 
potential physiological ligand(s) during endocytosis. When we compare our results to 
some key concepts of integrin endocytosis, we find some interesting similarities. 
Integrins bind to members of the ECM and seem to be important for remodeling of the 
ECM, especially of fibronectin via binding to α5β1 integrin [345]. Integrins recycle back 
to the PM after internalization with a half-time of either 3 min or 10 min, depending on 
the pathway. Estimations consider that the population of integrins at the PM will traffic 
through the recycling pathway at least once every 30 min [346]. Our data suggests a 
slower turnover for CMG2, although we would need to address the recycling times more 
accurately.  
Our work places CMG2 into a context comparable with integrins, yet with a less 
dynamic turnover. This could be important in tissues that do not constantly undergo 
remodeling or that would need to be stabilized more than others. Regions with 
mechanical stress would need such a stabile reinforcement together with a tight control 
of ECM homeostasis. This could explain why HFS patients display nodules preferentially 
at sites of mechanical stress, sites that are particularly sensitive to loss of CMG2 function.  
This work significantly contributes to a more general understanding of CMG2’s 
physiological function, by providing important insight into receptor trafficking, its 
regulation and by identifying key proteins functionally interacting with CMG2. It 
therefore provides us with a solid groundwork for further research on this important 
protein.  
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